302 results on '"Peter J. Dyck"'
Search Results
2. Composite nerve conduction scores and signs for diagnosis and somatic staging of diabetic polyneuropathy: Mid North American ethnic cohort survey
- Author
-
Jenny L. Davies, Karen A. Lodermeier, Diane M. Klein, Rickey E. Carter, P. James B. Dyck, William J. Litchy, and Peter J. Dyck
- Subjects
Cellular and Molecular Neuroscience ,Physiology ,Physiology (medical) ,Neurology (clinical) - Published
- 2023
3. Risk factors for lumbosacral radiculoplexus neuropathy
- Author
-
Marcus V. Pinto, Peng‐Soon Ng, Ruple S. Laughlin, Prabin Thapa, Catarina Aragon Pinto, Shahar Shelly, Kamal Shouman, Peter J. Dyck, and P. James B. Dyck
- Subjects
Stroke ,Cellular and Molecular Neuroscience ,Diabetic Neuropathies ,Risk Factors ,Physiology ,Physiology (medical) ,Lumbosacral Plexus ,Humans ,Neurology (clinical) ,Article ,Autoimmune Diseases - Abstract
Recently, our group found an association between diabetes mellitus (DM) and lumbosacral radiculoplexus neuropathy (LRPN) in Olmsted County, Minnesota; we found a higher risk (odds ratio [OR], 7.91) for developing LRPN in diabetic compared with nondiabetic patients. However, the influence of other comorbidities and anthropomorphic variables was not studied.Demographic and clinical data from 59 LRPN patients and 177 age/sex-matched controls were extracted using the Rochester LRPN epidemiological study. Differences between groups were compared by chi-square/Fisher exact test or Wilcoxon rank-sum test. Uni- and multivariate logistic regression analysis were performed.Factors predictive of LRPN on univariate analysis were DM (OR, 7.91; 95% confidence interval [CI], 4.11-15.21), dementia (OR, 6.36; 95% CI, 1.13-35.67), stroke (OR, 3.81; 95% CI, 1.32-11.01), dyslipidemia (OR, 2.844; 95% CI, 1.53-5.27), comorbid autoimmune disorders (OR, 2.72; 95% CI, 1.07-6.93), hypertension (OR, 2.25; 95% CI, 1.2-4.13), obesity (OR, 2.05; 95% CI, 1.11-3.8), body mass index (BMI) (OR, 1.1; 95% CI, 1.04-1.15), and weight (OR, 1.02; 95% CI, 1.009-1.037). On multivariate logistic regression analysis only DM (OR, 8.03; 95% CI, 3.86-16.7), comorbid autoimmune disorders (OR, 4.58; 95% CI, 1.45-14.7), stroke (OR, 4.13; 95% CI, 1.2-14.25), and BMI (OR, 1.07; 95% CI, 1.01-1.13) were risk factors for LRPN.DM is the strongest risk factor for the development of LRPN, followed by comorbid autoimmune disorders, stroke, and higher BMI. Altered metabolism and immune dysfunction seem to be the most influential factors in the development of LRPN.
- Published
- 2022
4. Pure Motor Onset and IgM-Gammopathy Occurrence in Multifocal Acquired Demyelinating Sensory and Motor Neuropathy
- Author
-
Kamal Shouman, Michelle L. Mauermann, Robert J. Spinner, Benjamin M. Howe, JaNean Engelstad, Peter J. Dyck, Grayson Beecher, Bruce V. Taylor, Christopher J. Klein, Shahar Shelly, John Mills, Divyanshu Dubey, Elie Naddaf, P. James B. Dyck, Sarah E. Berini, and Jennifer M. Martinez-Thompson
- Subjects
medicine.medical_specialty ,biology ,business.industry ,medicine.medical_treatment ,Autoantibody ,Mismatch negativity ,Sensory system ,Immunotherapy ,medicine.disease ,Gastroenterology ,Immunoglobulin M ,Internal medicine ,Gammopathy ,biology.protein ,Medicine ,Neurology (clinical) ,business ,Motor neuropathy ,Multifocal motor neuropathy - Abstract
Background and ObjectivesTo longitudinally investigate patients with multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), quantifying timing and location of sensory involvements in motor onset patients, along with clinicohistopathologic and electrophysiologic findings to ascertain differences in patients with and without monoclonal gammopathy of uncertain significance (MGUS).MethodsPatients with MADSAM seen at Mayo Clinic and tested for monoclonal gammopathy and ganglioside antibodies were retrospectively reviewed (January 1, 2007–December 31, 2018).ResultsOf 76 patients with MADSAM, 53% had pure motor, 16% pure sensory, 30% sensorimotor, and 1% cranial nerve onsets. Motor-onset patients were initially diagnosed with multifocal motor neuropathy (MMN). MGUS occurred in 25% (89% immunoglobulin M [IgM] subtype), associating with ganglioside autoantibodies (p < 0.001) and higher IgM titers (p < 0.04). Median time to sensory involvements (confirmed by electrophysiology) in motor onset patients was 18 months (range 6–180). Compared to initial motor nerve involvements, subsequent sensory findings were within the same territory in 35% (14/40), outside in 20% (8/40), or both in 45% (18/40). Brachial and lumbosacral plexus MRI was abnormal in 87% (34/39) and 84% (21/25), respectively, identifying hypertrophy and increased T2 signal predominantly in brachial plexus trunks (64%), divisions (69%), and cords (69%), and intrapelvic sciatic (64%) and femoral (44%) nerves. Proximal fascicular nerve biopsies (n = 9) more frequently demonstrated onion-bulb pathology (p = 0.001) and endoneurial inflammation (p = 0.01) than distal biopsies (n = 17). MRI and biopsy findings were similar among patient subgroups. Initial Inflammatory Neuropathy Cause and Treatment (INCAT) disability scores were higher in patients with MGUS relative to without (p = 0.02). Long-term treatment responsiveness by INCAT score reduction ≥1 or motor Neuropathy Impairment Score (mNIS) >8-point reduction occurred in 75% (49/65) irrespective of MGUS or motor onsets. Most required ongoing immunotherapy (86%). Patients with MGUS more commonly required dual-agent immunotherapy for stability (p = 0.02).DiscussionPure motor onsets are the most common MADSAM presentation. Long-term follow-up, repeat electrophysiology, and nerve pathology help distinguish motor onset MADSAM from MMN. Better long-term immunotherapy responsiveness occurs in motor onset MADSAM compared to MMN reports. Patients with MGUS commonly require dual immunotherapy.Classification of EvidenceThis study provides Class II evidence that most clinical, electrophysiologic, and histopathologic findings were similar between patients with MADSAM with and without MGUS.
- Published
- 2021
5. Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy
- Author
-
Kimberly K. Amrami, Peter J. Dyck, Divyanshu Dubey, Kamal Shouman, Rocio Vazquez Do Campo, Ja Nean K. Engelstad, Shahar Shelly, Robert J. Spinner, P. James B. Dyck, Pritikanta Paul, and Christopher J. Klein
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Sensory loss ,Sensory system ,Neurological examination ,Polyradiculoneuropathy ,Polyradiculopathy ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Somatosensory evoked potential ,Gait Ataxia ,Medicine ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Sensory nerve - Abstract
ObjectiveSensory loss with normal nerve conduction studies (NCS) from focal sensory root inflammatory demyelination is characteristic of chronic immune sensory polyradiculopathy (CISP). However, nonpure cases involving motor and distal sensory nerves exist (CISP-plus). We hypothesize that CISP-plus and CISP are fundamentally part of the same syndrome through comparison of clinical, neurophysiologic, and pathologic features.MethodsCISP-plus (primary dorsal root with lesser motor and sensory nerve involvement) and CISP cases were retrospectively analyzed (1986–2019).ResultsWe identified 44 CISP-plus and 28 CISP cases (n = 72) with 86% (38/44) of patients with CISP-plus and 79% (22/28) of patients with CISP experiencing imbalance. On examination, large fiber sensory loss was present in 98% (43/44) of patients with CISP-plus and 96% (27/28) of patients with CISP. Gait ataxia was evident in 93% (41/44) of patients with CISP-plus and 79% (22/28) of patients with CISP. Mild distal weakness was common in CISP-plus (75%, 33/44). NCS showed mild abnormalities in all patients with CISP-plus and were normal (by definition) in all patients with CISP. Elevated CSF protein, slowing of somatosensory evoked potentials, and MRI root enhancement occurred in most CISP-plus and CISP cases. Eleven CISP-plus nerve biopsies showed loss of large myelinated fibers and onion-bulb formations, most prominent in rootlet biopsies. Immunotherapy resulted in marked improvement of gait ataxia in 84% (27/32) of patients with CISP-plus and 93% (13/14) of patients with CISP with return to normal neurologic examination in half (25/46).ConclusionThe recognition of CISP-plus expands the spectrum of CIDP by combining CISP-plus (predominant sensory polyradiculopathy with mild motor and sensory nerve involvement) with pure CISP (focal sensory polyradiculopathy) together as proximal sensory CIDP.
- Published
- 2021
6. Lumbosacral Radiculoplexus Neuropathy
- Author
-
P. James B. Dyck, Benjamin M. Howe, Prabin Thapa, Peter J. Dyck, Marcus V. Pinto, Ruple S. Laughlin, and Peng Soon Ng
- Subjects
Adult ,Male ,Weakness ,medicine.medical_specialty ,Referral ,Minnesota ,Lumbosacral Plexus ,Population ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Modified Rankin Scale ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Radiculopathy ,education ,Aged ,Aged, 80 and over ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Median Neuropathy ,Middle Aged ,medicine.disease ,Female ,Neurology (clinical) ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Lumbosacral joint - Abstract
ObjectiveTo determine whether patients in the community with lumbosacral radiculoplexus neuropathy (LRPN) have milder neuropathy than referral patients, we characterized the outcomes and survival of population-based compared to referral-based LRPN cohorts.BackgroundPreviously, we found that the incidence of LRPN is 4.16/100,000/y, a frequency greater than other inflammatory neuropathies. The survival of patients with LRPN is uncharacterized.MethodsSixty-two episodes in 59 patients with LRPN were identified over 16 years (2000–2015). Clinical findings were compared to previous referral-based LRPN cohorts. Survival data were compared to those of age- and sex-matched controls.ResultsAt LRPN diagnosis, median age was 70 years, median Neuropathy Impairment Score (NIS) 22 points, 92% had pain, 95% had weakness, 23% were wheelchair-bound, and median modified Rankin Scale score (mRS) was 3 (range 1–4). At last follow-up, median NIS improved to 17 points (p < 0.001) with 56% having ≥4 points improvement, 16% were wheelchair-bound, and median mRS was 2. Compared to referral-based LRPN cohorts, community patients with LRPN had less impairment, less bilateral disease (37% vs 92%), and less wheelchair usage (23% vs 49%). LRPN survival was 86% at 5 years and 55% at 10 years. Compared to age- and sex-matched controls, patients with LRPN had 76% increased risk of death (p = 0.016). In multivariate analysis, diabetes, age, stroke, chronic kidney disease, peripheral artery disease, and coronary artery disease were significant mortality risk factors but LRPN was not.ConclusionLRPN is a painful, paralytic, asymmetric, monophasic, sometimes bilateral pan-plexopathy that improves over time but leaves patients with impairment. Although having LRPN increases mortality, this increase is probably due to comorbidities (diabetes) rather than LRPN itself.
- Published
- 2021
7. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- Author
-
Shiangtung W. Jung, Li Jung Tai, Márcia Waddington-Cruz, William J. Litchy, Sotirios Tsimikas, Peter J. Dyck, Cecilia Monteiro, Gustavo Buchele, Julian D. Gillmore, Michela Brambatti, John L. Berk, Eugene Schneider, Yukio Ando, Teresa Coelho, Morie A. Gertz, Merrill D. Benson, Nicholas J. Viney, Louis O'Dea, Richard S. Geary, Brett P. Monia, Sami Khella, and Laura Obici
- Subjects
Oncology ,endocrine system ,medicine.medical_specialty ,Neurology ,Clinical Trials and Supportive Activities ,Phases of clinical research ,Neurodegenerative ,Placebo ,Study Protocol ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Phase 3 clinical trial ,Clinical Research ,Internal medicine ,medicine ,Antisense oligonucleotide ,030212 general & internal medicine ,Dosing ,Peripheral Neuropathy ,biology ,business.industry ,Amyloidosis ,Clinical study design ,Neurosciences ,Evaluation of treatments and therapeutic interventions ,nutritional and metabolic diseases ,medicine.disease ,Hereditary transthyretin-mediated amyloid polyneuropathy ,AKCEA-TTR-L-rx ,Clinical trial design ,Transthyretin ,Orphan Drug ,AKCEA-TTR-Lrx ,6.1 Pharmaceuticals ,biology.protein ,Neurology (clinical) ,business ,Polyneuropathy ,030217 neurology & neurosurgery - Abstract
Introduction AKCEA-TTR-LRx is a ligand-conjugated antisense (LICA) drug in development for the treatment of hereditary transthyretin amyloidosis (hATTR), a fatal disease caused by mutations in the transthyretin (TTR) gene. AKCEA-TTR-LRx shares the same nucleotide sequence as inotersen, an antisense medicine approved for use in hATTR polyneuropathy (hATTR-PN). Unlike inotersen, AKCEA-TTR-LRx is conjugated to a triantennary N-acetylgalactosamine moiety that supports receptor-mediated uptake by hepatocytes, the primary source of circulating TTR. This advanced design increases drug potency to allow for lower and less frequent dosing. The NEURO-TTRansform study will investigate whether AKCEA-TTR-LRx is safe and efficacious, with the aim of improving neurologic function and quality of life in hATTR-PN patients. Methods/Design Approximately 140 adults with stage 1 (independent ambulation) or 2 (requires ambulatory support) hATTR-PN are anticipated to enroll in this multicenter, open-label, randomized, phase 3 study. Patients will be assigned 6:1 to AKCEA-TTR-LRx 45 mg subcutaneously every 4 weeks or inotersen 300 mg once weekly until the prespecified week 35 interim efficacy analysis, after which patients receiving inotersen will receive AKCEA-TTR-LRx 45 mg subcutaneously every 4 weeks. All patients will then receive AKCEA-TTR-LRx through the remainder of the study treatment period. The final efficacy analysis at week 66 will compare the AKCEA-TTR-LRx arm with the historical placebo arm from the phase 3 trial of inotersen (NEURO-TTR). The primary outcome measures are between-group differences in the change from baseline in serum TTR, modified Neuropathy Impairment Score + 7, and Norfolk Quality of Life—Diabetic Neuropathy questionnaire. Conclusion NEURO-TTRansform is designed to determine whether targeted delivery of AKCEA-TTR-LRx to hepatocytes with lower and less frequent doses will translate into clinical and quality-of-life benefits for patients with hATTR-PN. Trial Registration The study is registered at ClinicalTrials.gov (NCT04136184) and EudraCT (2019-001698-10). Supplementary Information The online version contains supplementary material available at 10.1007/s40120-021-00235-6., Plain Language Summary Hereditary transthyretin amyloidosis with peripheral neuropathy (hATTR-PN for short) is a rare inherited condition.In hATTR-PN, a protein called transthyretin (TTR for short) builds up and damages nerves throughout the body.This neuropathy causes symptoms such as weakness, loss of sensation, and pain.Currently available medicines can slow disease progression, but researchers are looking for more effective treatments with fewer side effects.AKCEA-TTR-LRx is an investigational treatment for hATTR-PN.AKCEA-TTR-LRx prevents the liver from making TTR, reducing the amount that causes disease progression.It is similar to an existing treatment called inotersen, but designed for better delivery to the liver and is more potent.This article describes the NEURO-TTRansform study that will evaluate how effective AKCEA-TTR-LRx is for treating hATTR-PN.Around 140 adults with hATTR-PN from the USA, Canada, and Europe will be able to take part in this study.The study treatment period will be 85 weeks long. People will receive injections underneath the skin of either:AKCEA-TTR-LRx every 4 weeks, orInotersen once a week for 35 weeks, followed by a switch to AKCEA-TTR-LRx every 4 weeks.People may continue to receive AKCEA-TTR-LRx after the study treatment period ends.In this study, researchers will compare results from people who received AKCEA-TTR-LRx to results from people who received no active ingredients (called placebo) in a similar study (called NEURO-TTR).Researchers will measure the differences in peoples’:Neuropathy symptoms.Quality of life.TTR protein levels in the blood. Supplementary Information The online version contains supplementary material available at 10.1007/s40120-021-00235-6.
- Published
- 2021
8. Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy
- Author
-
Brian A. Crum, Kimberly K. Amrami, P. James B. Dyck, Matthew C. Kiernan, Robert J. Spinner, Michelle L. Mauermann, Bruce V. Taylor, Jennifer A. Tracy, and Peter J. Dyck
- Subjects
Adult ,Male ,0301 basic medicine ,Neural Conduction ,Mismatch negativity ,030105 genetics & heredity ,behavioral disciplines and activities ,Polyneuropathies ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Pathological ,Nerve biopsy ,Chronic axonal neuropathy ,medicine.diagnostic_test ,business.industry ,Polyradiculoneuropathy ,General Medicine ,medicine.disease ,Axons ,Pathophysiology ,Peripheral neuropathy ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Neurology ,Female ,Neurology (clinical) ,business ,Neuroscience ,psychological phenomena and processes ,030217 neurology & neurosurgery ,Multifocal motor neuropathy - Abstract
Objectives The objective of the study is to distinguish the mechanisms of disease for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN), which we believe to be fundamentally different. However, distinguishing the mechanisms is more difficult when the presentation of CIDP is motor-predominant, focal, or asymmetric. Methods We describe 3 focal, motor-predominant, representative cases that could be interpreted on clinical and/or electrophysiological grounds as either MMN or focal CIDP, and present pathological findings. Results We highlight pathological differences in these cases, and provide an argument that CIDP and MMN are distinct entities with different pathophysiological mechanisms-chronic demyelination for CIDP, and an immune-mediated attack on paranodal motor axons for MMN. Conclusions Based on clinical evaluation, electrophysiology, and nerve biopsy pathology, we can divide the conditions into inflammatory demyelinating neuropathy (focal CIDP) versus chronic axonal neuropathy (MMN). The divergent pathological findings provide further evidence that CIDP and MMN are fundamentally different disorders.
- Published
- 2020
9. <scp>mNIS</scp> +7 <scp>and lower limb function in inotersen treatment of</scp> hereditary transthyretin‐mediated amyloidosis
- Author
-
Janice F. Wiesman, Michael Polydefkis, William J. Litchy, Michelle L. Mauermann, P. James B. Dyck, Shiangtung W. Jung, Brenda F. Baker, Michael L. Pollock, Spencer D. Guthrie, John C. Kincaid, Peter J. Dyck, and Elizabeth J. Ackermann
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Physiology ,Oligonucleotides ,Diaphragmatic breathing ,030105 genetics & heredity ,inotersen ,Placebo ,Gastroenterology ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Double-Blind Method ,Heart Rate ,Physiology (medical) ,Internal medicine ,Reflex ,Heart rate ,medicine ,Humans ,Clinical Research Articles ,amyloidosis ,Clinical Research Article ,Amyloid Neuropathies, Familial ,Muscle Weakness ,biology ,business.industry ,mNIS+7 ,Amyloidosis ,Muscle weakness ,Middle Aged ,Oligonucleotides, Antisense ,medicine.disease ,lower limb function ,Transthyretin ,Treatment Outcome ,medicine.anatomical_structure ,Lower Extremity ,hATTR ,biology.protein ,Upper limb ,Female ,Neurology (clinical) ,medicine.symptom ,business ,Polyneuropathy ,030217 neurology & neurosurgery - Abstract
Introduction Inotersen, an antisense oligonucleotide inhibitor of transthyretin (TTR) protein production, demonstrated significant benefit versus placebo in the modified Neuropathy Impairment Score (NIS) +7 neurophysiologic tests (mNIS+7) in patients with hereditary TTR‐mediated amyloidosis (hATTR) with polyneuropathy. This analysis assessed the mNIS+7 components by anatomic location and the lower limb function (LLF) test. Methods Adults with hATTR in the NEURO‐TTR trial (NCT01737398) were randomly assigned to receive weekly doses of subcutaneous inotersen 300 mg or placebo for 65 weeks. The mNIS+7 and LLF were assessed at 35 and 66 weeks. Results All major mNIS+7 components (muscle weakness, muscle stretch reflexes, sensation) and the LLF showed significant efficacy in patients receiving inotersen versus placebo; however, NIS‐reflexes (upper limb), touch pressure (upper and lower limbs), and heart rate during deep breathing did not show significant effects. Discussion The results of this analysis reinforce the beneficial effect of inotersen on slowing neuropathy progression in patients with hATTR polyneuropathy., See article on pages 509–515 in this issue.
- Published
- 2020
10. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
- Author
-
William J. Litchy, Michael L. Pollock, P. James B. Dyck, Michelle L. Mauermann, Teresa Coelho, Chafic Karam, Michael Polydefkis, Sami Khella, Janice F. Wiesman, Thomas H. Brannagan, Márcia Waddington Cruz, Spencer D. Guthrie, John L. Berk, Shiangtung W. Jung, Peter J. Dyck, Brenda F. Baker, Elizabeth J. Ackermann, and John C. Kincaid
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Physiology ,Oligonucleotides ,030105 genetics & heredity ,inotersen ,Placebo ,transthyretin ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,Post-hoc analysis ,Humans ,Medicine ,In patient ,Stage (cooking) ,Clinical Research Articles ,Aged ,amyloidosis ,Clinical Research Article ,Amyloid Neuropathies, Familial ,biology ,business.industry ,Amyloidosis ,Muscle weakness ,Middle Aged ,Oligonucleotides, Antisense ,medicine.disease ,Neuropathy Symptoms and Change ,Transthyretin ,Treatment Outcome ,hATTR ,Disease Progression ,Quality of Life ,biology.protein ,Autonomic symptoms ,Female ,Neurology (clinical) ,Symptom Assessment ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Introduction Hereditary transthyretin‐mediated amyloidosis (hATTR) manifests as multisystem dysfunction, including progressive polyneuropathy. Inotersen, an antisense oligonucleotide, improved the course of neuropathic impairment in patients with hATTR in the pivotal NEURO‐TTR study (NCT01737398). To determine inotersen's impact on symptoms and patients’ neuropathy experience, we performed a post hoc analysis of the Neuropathy Symptoms and Change (NSC) score. Methods Stage 1 or 2 hATTR patients were randomized to receive weekly subcutaneous inotersen or placebo for 65 weeks. NSC score was assessed at baseline and 35 and 66 weeks. Results At 66 weeks, inotersen‐treated patients had symptom stabilization as compared with worsening in patients receiving placebo, based on total NSC score. There were also improvements in the subdomains of muscle weakness, sensory, pain, and autonomic symptoms, and for various individual items. Discussion Inotersen treatment stabilized neuropathy symptoms, including autonomic symptoms, in patients with hATTR according to NSC score. Thus, the NSC may be an effective measure to assess neuropathy progression and patients’ neuropathy experience in clinical practice., See article on pages 502–508 in this issue.
- Published
- 2020
11. Variable differences of nerve conduction amplitudes versus velocities and distal latencies of healthy subjects assessed in ethnic cohorts
- Author
-
Reem Alhammad, William J. Litchy, Jenny L. Davies, Peter J. Dyck, P. James B. Dyck, and Rickey E. Carter
- Subjects
medicine.medical_specialty ,Physiology ,business.industry ,technology, industry, and agriculture ,Healthy subjects ,Snap ,Neural Conduction ,Action Potentials ,Audiology ,Nerve conduction velocity ,Healthy Volunteers ,Compound muscle action potential ,Cellular and Molecular Neuroscience ,Polyneuropathies ,Amplitude ,Nerve Fibers ,Physiology (medical) ,Cohort ,Sensory nerve action potential ,Medicine ,Humans ,Neurology (clinical) ,business ,Nerve conduction - Abstract
Variable differences of nerve conduction amplitudes vs velocities and distal latencies (DLs) of healthy subjects assessed in ethnic cohorts. Introduction/aims The variables affecting reference compound muscle (CMAP) and sensory nerve action potential (SNAP) amplitudes as compared to ones affecting conduction velocities and DLs have not been adequately evaluated in previous studies. In this report, this subject is studied in healthy subject cohorts mainly of Northern European extraction, Northern Plains Indians, and Latinos. Methods Nineteen variables and 18 attributes of nerve conductions (NCs) were assessed using highly standard testing conditions and techniques. Classification and Regression Tree analyses were used to assess variable differences among amplitudes, conduction velocities, and DLs. Results The most important variable affecting CMAP and SNAP amplitudes was age. For conduction velocities (CVs) and DLs, the variables were height, ethnic cohort, and age. Discussion The variables affecting attributes of NCs were similar for the three ethnic cohorts evaluated. The differences of variables affecting amplitudes compared to CVs and DLs need to be taken into account in interpretation of NC results and in setting reference limits for use in medical practice, epidemiology surveys, and therapeutic trials. Scores of CMAP and SNAP amplitudes are suitable measures of sensorimotor polyneuropathy severity, whereas conduction velocities and DLs reflect physiologic/pathologic abnormality of nerve fibers.
- Published
- 2021
12. Onion‐bulb patterns predict acquired or inherited demyelinating polyneuropathy
- Author
-
Jane E. Meyer, P. James B. Dyck, Jennifer A. Tracy, Ja Nean K. Engelstad, Peter J. Dyck, and Christopher J. Klein
- Subjects
Adult ,Male ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,Adolescent ,Physiology ,Biopsy ,Inflammation ,030105 genetics & heredity ,Onion bulb ,Young Adult ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Muscle nerve ,Charcot-Marie-Tooth Disease ,Clinical history ,Physiology (medical) ,medicine ,Humans ,Peripheral Nerves ,Demyelinating polyneuropathy ,Demyelinating polyneuropathies ,Inherited neuropathy ,Aged ,business.industry ,Middle Aged ,medicine.disease ,Peripheral neuropathy ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Female ,Schwann Cells ,Neurology (clinical) ,medicine.symptom ,Hereditary Sensory and Motor Neuropathy ,business ,Myelin Proteins ,030217 neurology & neurosurgery - Abstract
INTRODUCTION Onion-bulbs (OB) are concentrically layered Schwann-cell processes, surrounding nerve fibers, occurring in both inherited and acquired demyelinating polyneuropathies. We investigated whether OB patterns (generalized, mixed, or focal) correlate with acquired or inherited neuropathies. METHODS One hundred thirty-one OB-rich nerve biopsies were graded for OB pattern and inflammation without knowledge of clinical history. We classified inherited (n = 49) or acquired (n = 82) neuropathies based solely on clinical history. RESULTS Fifty-one biopsies had generalized (34 inherited vs. 17 acquired, P
- Published
- 2019
13. Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy
- Author
-
Marcus V. Pinto, Márcia Waddington-Cruz, Linde E. Gove, Steven G. Hughes, Bryan M. McCauley, P. James B. Dyck, Elizabeth J. Ackermann, and Peter J. Dyck
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Sensory system ,Gastroenterology ,Cohort Studies ,Polyneuropathies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Sensation ,medicine ,Humans ,Aged ,Skin ,Aged, 80 and over ,Neurologic Examination ,Amyloid Neuropathies, Familial ,biology ,business.industry ,Amyloidosis ,Middle Aged ,medicine.disease ,Transthyretin ,030104 developmental biology ,Peripheral neuropathy ,medicine.anatomical_structure ,Neurology ,Touch ,Sensory Thresholds ,Sensation Disorders ,Cohort ,biology.protein ,Upper limb ,Female ,Neurology (clinical) ,business ,Polyneuropathy ,Algorithms ,030217 neurology & neurosurgery - Abstract
Objective Report on the kind and distribution of somatotopic sensation loss and its utility in assessing severity of sensation loss in study of a large international cohort of patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). Methods Smart Somatotopic Quantitative Sensation Testing (S ST QSTing) using Computer Assisted Sensation Evaluator IVc (CASE IVc) was used to assess the somatotopic distribution of touch pressure (TP) and heat pain (HP) sensation loss twice of untreated hATTR-PN patients in the Ionis NEURO-TTR trial ( www.clinicaltrials.gov , NCT01737398). Results Of the studied cohort of 169 patients, 163 (97%) had sensation loss, both TP and HP in 121/169 (75%), TP only in 39/169 (23%), and HP only in 3/169 (2%). Sensation loss typically affected both lower (152/169–90%) and upper limb (135/169–82%), and overall TP sensation loss was greater than HP loss, except for early-onset Val30Met patients in which HP exceeded TP loss. Conclusion Using S ST QSTing, a highly quantitated, standardized, referenced, and automated QSTing approach of the body's surface distribution of sensation loss we have shown that: 1) reliable and useful measurement of the body surface distribution of sensation loss is possible; 2) this measure is abnormal in most patients with hATTR-PN and is an indication of polyneuropathy severity; and 3) cutaneous sensation loss involves both large and small sensory fibers in this disease but slightly more small fibers in early onset Val30Met patients.
- Published
- 2018
14. Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach
- Author
-
Elie Naddaf, Amro M. Stino, P. James B. Dyck, and Peter J. Dyck
- Subjects
0301 basic medicine ,Activities of daily living ,Physiology ,medicine.medical_treatment ,Neural Conduction ,Paraproteinemias ,CIDP, diagnosis, IVIg, plasma exchange, steroids, treatment ,Medical Overuse ,030105 genetics & heredity ,Amyloid Neuropathies ,Infusions, Subcutaneous ,0302 clinical medicine ,Cerebrospinal fluid ,Adrenal Cortex Hormones ,Charcot-Marie-Tooth Disease ,Outcome Assessment, Health Care ,Paraneoplastic Polyneuropathy ,Cerebrospinal Fluid ,Plasma Exchange ,Electrodiagnosis ,Immunoglobulins, Intravenous ,Sensory loss ,POEMS Syndrome ,Disease Progression ,medicine.symptom ,medicine.medical_specialty ,Treatment response ,Weakness ,Diagnosis, Differential ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Physiology (medical) ,Internal medicine ,Health Sciences ,medicine ,Diagnostic biomarker ,Humans ,Immunologic Factors ,Peripheral Nerves ,Diagnostic Errors ,business.industry ,FOS: Clinical medicine ,Neurosciences ,Polyradiculoneuropathy ,Immunotherapy ,medicine.disease ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Immunoglobulin G ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patients�� ability to walk and perform activities of daily living independently. With the lack of a diagnostic biomarker, the diagnosis relies on clinical suspicion, clinical findings, and the demonstration of demyelinating changes on electrodiagnostic (EDx) testing and nerve pathology. As a result, patients can often be misdiagnosed with CIDP and unnecessarily treated with immunotherapy. Interpreting the EDx testing and cerebrospinal fluid findings in light of the clinical phenotype, recognizing atypical forms of CIDP, and screening for CIDP mimickers are the mainstays of the approach to patients suspected of having CIDP, and are detailed in this review. We also review the currently available treatment options, including intravenous immunoglobulin (IVIg), corticosteroids (CCS), and plasma exchange (PE), and discuss how to approach treatment���refractory cases. Finally, we emphasize the need to adopt objective outcome measures to monitor treatment response.
- Published
- 2020
15. Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
- Author
-
David H. Adams, John L. Berk, Fabio Barroso, Shiangtung W. Jung, M D Benson, Peter D. Gorevic, Isabel Conceição, Fabrizio Salvi, A. K. Wang, Peter J. Dyck, Brian M. Drachman, Arnt V. Kristen, Giuseppe Vita, V. Plante-Bordeneuve, Acary Souza Bulle Oliveira, Stephen B. Heitner, Edward Gane, Laura Obici, Spencer D. Guthrie, Michael L. Pollock, Josep Maria Campistol Plana, Hartmut Schmidt, M. Waddington Cruz, Morton Scheinberg, T. Coelho, Jesse Kwoh, Giampaolo Merlini, Josep Gamez, Thomas H. Brannagan, Michael Polydefkis, Morie A. Gertz, S.G. Hughes, and Carol J. Whelan
- Subjects
Male ,medicine.medical_specialty ,Diabetic neuropathy ,Oligonucleotides ,Disease ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,peripheral neuropathies ,Internal medicine ,medicine ,Humans ,Prealbumin ,030212 general & internal medicine ,genetic and inherited disorders ,Amyloid Neuropathies, Familial ,biology ,business.industry ,Amyloidosis ,Middle Aged ,medicine.disease ,Neuropathies ,polyneuropathy ,Transthyretin ,Neurology ,Tolerability ,Quality of Life ,biology.protein ,Female ,Original Article ,Neurology (clinical) ,business ,Polyneuropathy ,030217 neurology & neurosurgery - Abstract
Background and purpose: Hereditary transthyretin (hATTR) amyloidosis causes progressive polyneuropathy resulting from transthyretin (TTR) amyloid deposition throughout the body, including the peripheral nerves. The efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of TTR protein production, were demonstrated in the pivotal NEURO-TTR study in patients with hATTR polyneuropathy. Here, the long-term efficacy and safety of inotersen are assessed in an ongoing open-label extension (OLE) study. Methods: Patients who completed NEURO-TTR were eligible to enroll in the OLE (NCT02175004). Efficacy assessments included the modified Neuropathy Impairment Score plus seven neurophysiological tests composite score (mNIS + 7), the Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN) questionnaire total score and the Short-Form 36 Health Survey (SF-36) Physical Component Summary (PCS) score. Safety and tolerability were also assessed. Results: Overall, 97% (135/139) of patients who completed NEURO-TTR enrolled in the OLE. Patients who received inotersen for 39 cumulative months in NEURO-TTR and the OLE continued to show benefit; patients who switched from placebo to inotersen in the OLE demonstrated improvement or stabilization of neurological disease progression by mNIS + 7, Norfolk QOL-DN and SF-36 PCS. No new safety concerns were identified. There was no evidence of increased risk for grade 4 thrombocytopenia or severe renal events with increased duration of inotersen exposure. Conclusion: Inotersen slowed disease progression and reduced deterioration of quality of life in patients with hATTR polyneuropathy. Early treatment with inotersen resulted in greater long-term disease stabilization than delayed initiation. Routine platelet and renal safety monitoring were effective; no new safety signals were observed. info:eu-repo/semantics/publishedVersion
- Published
- 2020
16. Porphyria: A rare differential diagnosis of polyradiculoneuropathy
- Author
-
Sarah E. Berini, James P. Klaas, Farwa Ali, Neeraj Kumar, and Peter J. Dyck
- Subjects
Adult ,Male ,medicine.medical_specialty ,Abdominal pain ,business.industry ,Polyradiculoneuropathy ,medicine.disease ,Dermatology ,Diagnosis, Differential ,Porphyrias ,Porphyria ,Neurology ,Seizure Disorders ,medicine ,Humans ,Neurology (clinical) ,medicine.symptom ,Differential diagnosis ,business - Published
- 2019
17. Peripheral neuropathy associated with silver toxicity
- Author
-
Paul J. Jannetto, Peter J. Dyck, Elie Naddaf, David L. Murray, and P. James B. Dyck
- Subjects
Adult ,Silver ,Morgellons Disease ,Self Medication ,Pharmacology ,Silver nanoparticle ,Proinflammatory cytokine ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,medicine ,Humans ,Argyria ,030212 general & internal medicine ,Chemistry ,Peripheral Nervous System Diseases ,medicine.disease ,Endothelial stem cell ,medicine.anatomical_structure ,Peripheral neuropathy ,Peripheral nervous system ,Toxicity ,Female ,Dermatologic Agents ,Neurology (clinical) ,030217 neurology & neurosurgery - Abstract
Silver is known to be a potent bactericidal agent. It has a proinflammatory effect by inducing inflammatory cytokines and reactive oxygen species. Silver can also have a direct cytotoxic effect on immune cells and can cause endothelial cell injury.1 At low levels, silver is thought to be nontoxic. It only deposits in the skin and causes a silver-blue discoloration called argyria. Lately, there has been an increase in the use of silver nanoparticles as antimicrobial agents or via alternative medicine, which reignited interest in further studying silver toxicity. In the CNS, silver can disrupt the blood–brain barrier and be toxic to neurons and astrocytes.1 There have been case reports of silver toxicity associated with seizures, cortical basal degeneration, and psychosis.2–4 On the other hand, the effect of silver on the peripheral nervous system remains poorly explored. In this report, we present a case of a peripheral neuropathy associated with argyria with detailed clinical, laboratory, and histopathologic findings.
- Published
- 2019
18. Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis
- Author
-
Anna Mazzeo, Carol J. Whelan, Morie A. Gertz, John L. Berk, Violaine Planté-Bordeneuve, Isabel Conceição, Brian M. Drachman, Hartmut Schmidt, Peter D. Gorevic, Merrill D. Benson, Arnt V. Kristen, Josep Maria Campistol Plana, Michael Polydefkis, Teresa Coelho, Giampaolo Merlini, Josep Gamez, Annabel K. Wang, Peter J. Dyck, Thomas H. Brannagan, Peter Aquino, Arvind Narayana, Laura Obici, and Kemi Olugemo
- Subjects
Transthyretin ,medicine.medical_specialty ,Neurology ,biology ,business.industry ,Amyloidosis ,biology.protein ,Medicine ,Neurology (clinical) ,business ,medicine.disease ,Polyneuropathy ,Dermatology - Published
- 2021
19. Assessing mNIS+7 Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
- Author
-
Karen A. Lodermeier, Thomas H. Brannagan, Joao Vasco Ferreira, Steven G. Hughes, Violaine Planté-Bordeneuve, Rickey E. Carter, Jessica Robinson-Papp, Rito Bergemann, Peter J. Dyck, Christina Alves, Julie Khoury, John C. Kincaid, John L. Berk, Matilde Laura, Samar S. Ayache, Carol J. Whelan, Brian M. Drachman, Isabel Conceição, Merrill D. Benson, Sami Khella, Michael Polydefkis, Teresa Coelho, Morie A. Gertz, William J. Litchy, Hayet Salhi, Vinay Chaudhry, Stephen B. Heitner, David H. Adams, Giampaolo Merlini, Andrea Cortese, Janice F. Wiesman, P. James B. Dyck, Namita Goyal, Márcio Cardoso, Christopher J. Klein, Katherine Ruzhansky, Annabel K. Wang, Michelle L. Mauermann, Marcus V. Pinto, Márcia Waddington-Cruz, Jenny L. Davies, Céline Labeyrie, Peter D. Gorevic, and Elizabeth J. Ackermann
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Physiology ,business.industry ,Neurologic Signs ,medicine.disease ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,030104 developmental biology ,0302 clinical medicine ,Peripheral neuropathy ,Muscle nerve ,Physiology (medical) ,Sensation ,Severity of illness ,medicine ,Physical therapy ,Neurology (clinical) ,Abnormality ,business ,Polyneuropathy ,030217 neurology & neurosurgery ,Cohort study - Abstract
Introduction Polyneuropathy signs (Neuropathy Impairment Score, NIS), neurophysiologic tests (m+7Ionis ), disability, and health scores were assessed in baseline evaluations of 100 patients entered into an oligonucleotide familial amyloidotic polyneuropathy (FAP) trial. Methods We assessed: (1) Proficiency of grading neurologic signs and correlation with neurophysiologic tests, and (2) clinometric performance of modified NIS+7 neurophysiologic tests (mNIS+7Ionis ) and its subscores and correlation with disability and health scores. Results The mNIS+7Ionis sensitively detected, characterized, and broadly scaled diverse polyneuropathy impairments. Polyneuropathy signs (NIS and subscores) correlated with neurophysiology tests, disability, and health scores. Smart Somatotopic Quantitative Sensation Testing of heat as pain 5 provided a needed measure of small fiber involvement not adequately assessed by other tests. Conclusions Specially trained neurologists accurately assessed neuropathy signs as compared to referenced neurophysiologic tests. The score, mNIS+7Ionis , broadly detected, characterized, and scaled polyneuropathy abnormality in FAP, which correlated with disability and health scores. Muscle Nerve 56: 901-911, 2017.
- Published
- 2017
20. Genomic analysis reveals frequentTRAF7mutations in intraneural perineuriomas
- Author
-
P. James B. Dyck, Peter J. Dyck, Yanhong Wu, Robert J. Spinner, Mark E. Jentoft, Georges Mer, Michelle L. Mauermann, and Christopher J. Klein
- Subjects
Pathology ,medicine.medical_specialty ,Whole genome microarray ,Chromosome ,Extremity weakness ,Biology ,Bioinformatics ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Perineurioma ,Neurology ,030220 oncology & carcinogenesis ,Etiology ,medicine ,Causal link ,Neurology (clinical) ,030217 neurology & neurosurgery ,Exome sequencing - Abstract
Intraneural perineuriomas are benign peripheral nerve sheath tumors that cause progressive debilitating focal extremity weakness. The etiology of perineuriomas is largely unknown. We utilized whole exome sequencing, copy number algorithm evaluation and high-resolution whole genome microarray to investigate for a genetic causal link of intraneural perineuriomas. Ten of 16 (60%) tumor cases had mutations in the WD40 domain of TRAF7, the same location for causal mutations of meningiomas. Two additional perineurioma cases had large chromosomal abnormalities in multiple chromosomes, including chromosome 22q. This study identifies a common cause for intraneural perineuriomas and an unexpected shared pathogenesis with intracranial meningiomas. This article is protected by copyright. All rights reserved.
- Published
- 2017
21. Blink reflex role in algorithmic genetic testing of inherited polyneuropathies
- Author
-
Wei Wang, Jayawant N. Mandrekar, Christopher J. Klein, William J. Litchy, and Peter J. Dyck
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Adolescent ,Physiology ,Primary demyelination ,Neural Conduction ,Cohort Studies ,Polyneuropathies ,Young Adult ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Physical medicine and rehabilitation ,Physiology (medical) ,medicine ,Humans ,Genetic Testing ,Corneal reflex ,Latency (engineering) ,Demyelinating polyneuropathy ,Child ,Inherited polyneuropathy ,Aged ,Genetic testing ,Blinking ,medicine.diagnostic_test ,Electromyography ,business.industry ,Nuclear Proteins ,Middle Aged ,030104 developmental biology ,Child, Preschool ,Mutation ,Reflex ,Regression Analysis ,Female ,Neurology (clinical) ,Genetic diagnosis ,business ,Myelin P0 Protein ,Neuroscience ,Algorithms ,Myelin Proteins ,030217 neurology & neurosurgery ,Transcription Factors - Abstract
Introduction In severely affected inherited polyneuropathy patients, primary demyelination can be difficult to determine by routine extremity limb nerve conduction studies (NCS). Blink reflexes may help classify severe polyneuropathies as either axonal or demyelinating. However, blink reflex studies have not been studied systematically in any genetically confirmed cohort. Methods Patients with a genetic diagnosis who had undergone blink reflex testing and extremity NCS were identified retrospectively. Blink reflex R1 latency, extremity NCS, and severity were compared. Results We identified 26 demyelinating and 23 axonal, genetically confirmed cases, including 20 with PMP22 duplications. In 12 (25%), the ulnar CMAP amplitude was ≤0.5 mV making electrophysiological classification difficult. However, the R1-latency cutoff of >13 ms (demyelinating) robustly classified all patients regardless of severity. Conclusions We show that blink reflex studies are reliable for identification of inherited demyelinating polyneuropathy regardless of severity and can facilitate algorithmic decisions in genetic testing. Muscle Nerve 55: 316-322, 2017.
- Published
- 2016
22. Lumbosacral radiculoplexus neuropathy: Incidence and the association with diabetes mellitus
- Author
-
Ruple S. Laughlin, Peng Soon Ng, Marcus V. Pinto, P. James B. Dyck, Prabin Thapa, and Peter J. Dyck
- Subjects
Adult ,Male ,medicine.medical_specialty ,Minnesota ,Population ,Lumbosacral Plexus ,Polyradiculoneuropathy ,Article ,Prediabetic State ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Rochester Epidemiology Project ,Diabetic Neuropathies ,Diabetes mellitus ,Internal medicine ,medicine ,Diabetes Mellitus ,Humans ,030212 general & internal medicine ,Risk factor ,education ,Aged ,Aged, 80 and over ,Glycated Hemoglobin ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Incidence ,Middle Aged ,medicine.disease ,Lumbosacral plexus ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Lumbosacral joint - Abstract
ObjectiveTo determine the previously unknown incidence of lumbosacral radiculoplexus neuropathy (LRPN) and its association with diabetes mellitus (DM).MethodsLRPN defined by clinical and electrophysiologic criteria was identified among Olmsted County, Minnesota, residents during a 16-year period (2000–2015) using the unique facilities of the Rochester Epidemiology Project. DM was ascertained using American Diabetes Association criteria.ResultsOf 1,892 medical records reviewed, 59 patients (33 men, 26 women) were identified as having LRPN. The median age was 70 years (range 24–88 years) and the median time of onset of symptoms to diagnosis was 2 months (range 1–72 months). DM was more frequent in patients with LRPN than in controls (39/59 vs 35/177, p < 0.001) but not in those with pre-DM (10/20 vs 55/142, p = 0.336). LRPN recurred in 3 patients with DM resulting in 62 LRPN episodes during the study period. The overall incidence of LRPN was 4.16/100,000/y (95% confidence interval [CI] 3.13–5.18). The incidences of LRPN among DM and non-DM groups were 2.79/100,000/y (95% CI 1.94–3.64) and 1.27/100,000/y (95% CI 0.71–1.83), respectively. The odds of LRPN among patients with DM and pre-DM was 7.91 (95% CI 4.11–15.21) and 1.006 (95% CI 1.004–1.012), respectively.ConclusionsLRPN incidence in Olmsted County of 4.16/100,000/y makes LRPN a common inflammatory neuropathy and is higher than that of other immune-mediated neuropathies (acute or chronic inflammatory demyelinating polyradiculoneuropathy, brachial plexus neuropathy) assessed within the same population. DM is a major risk factor for LRPN and thus justifies the continued classification of LRPN into diabetic and nondiabetic forms.
- Published
- 2019
23. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7
- Author
-
Alejandra González-Duarte, P. James B. Dyck, Laura Obici, I. Antonino, William J. Litchy, Michael Polydefkis, Janice F. Wiesman, and Peter J. Dyck
- Subjects
medicine.medical_specialty ,Amyloid Neuropathies, Familial ,business.industry ,Amyloidosis ,Muscle weakness ,Sensory loss ,Disease ,medicine.disease ,Clinical trial ,03 medical and health sciences ,Polyneuropathies ,0302 clinical medicine ,Neurology ,Internal medicine ,Clinical endpoint ,Medicine ,Humans ,030212 general & internal medicine ,Neurology (clinical) ,medicine.symptom ,Symptom Assessment ,business ,Polyneuropathy ,030217 neurology & neurosurgery ,Disease burden - Abstract
Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction. Measures used to assess polyneuropathy in other diseases have been tested as endpoints in hATTR amyloidosis clinical trials (i.e. Neuropathy Impairment Score [NIS], NIS-lower limb, and NIS + 7), yet the unique nature of the polyneuropathy in this disease has necessitated modifications to these scales. In particular, the heterogeneous impairment and the aggressive disease course have been key drivers in developing scales that better capture the disease burden and progression of polyneuropathy in hATTR amyloidosis. The modified NIS + 7 (mNIS + 7) scale was specifically designed to assess polyneuropathy impairment in patients with hATTR amyloidosis, and has been the primary endpoint in two recent, phase III studies in this disease. The mNIS + 7 uses highly standardized, quantitative, and referenced assessments to quantify decreased muscle weakness, muscle stretch reflexes, sensory loss, and autonomic impairment. Physicians using this scale in clinical trials should be specifically trained and monitored to minimize variability. This article discusses the different scales that have been/are being used to assess polyneuropathy in patients with hATTR amyloidosis, their correlation with other disease assessments, and reflects on how and why scales have evolved to the latest iteration of mNIS + 7.
- Published
- 2018
24. Expanded teased nerve fibre pathological conditions in disease association
- Author
-
Janean K. Engelstad, P. James B. Dyck, Peter J. Dyck, Christopher J. Klein, Chenjing Sun, Marcus V. Pinto, and Min Xu
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Lymphoma, B-Cell ,Nerve fibre ,Disease Association ,Amyloid Neuropathies ,03 medical and health sciences ,Myelin ,0302 clinical medicine ,Nerve Fibers ,Biopsy ,medicine ,Humans ,Pathological ,Aged ,medicine.diagnostic_test ,business.industry ,Polyradiculoneuropathy ,Middle Aged ,medicine.disease ,Glycogen Storage Disease ,Psychiatry and Mental health ,medicine.anatomical_structure ,Peripheral neuropathy ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Case-Control Studies ,Surgery ,Female ,Neurology (clinical) ,Nervous System Diseases ,business ,030217 neurology & neurosurgery ,Cellular Debris - Abstract
ObjectiveTo describe an expanded teased nerve fibre classification in disease association.MethodsWe reviewed four newly proposed teased nerve fibre types (Types J–M): Type J, rope-like fibres; K, fibril-like clumps of osmium positivity; L, cellular debris along and within nerve fibres; M, circular axonal inclusions surrounded by thin myelin. Different clinical pathological entities were studied for these fibre types including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP: N=20); amyloid polyneuropathy (N=20); intraneural B-cell lymphoma (N=20) or adult-onset polyglucosan body disease (APBD: N=6) in comparison with 112 disease controls. Student’s t-test was used to test significance of association between the identified fibre types and the specific clinical diagnosis.ResultsEach fibre type significantly associated (pType J, 60% of CIDP cases; Type K, 75% of amyloid cases; Type L, 75% of intraneural lymphoma cases; Type M, 100% of APBD cases. Rarely were these fibres found in the other disease control cases ≤3% of cases. In three cases, the teased fibre findings were so striking additional paraffin nerve preparations were made to make the pathological diagnosis when initial paraffin sections were non-diagnostic.ConclusionsTeased nerve fibre Types J–M associate with commonly seen pathological diagnosis and are helpful in the consideration of specific neuropathy diagnoses.
- Published
- 2018
25. Method of levels not limits for assessment of cooling detection thresholds
- Author
-
Peter J. Dyck and P. James B. Dyck
- Subjects
Cold Temperature ,Healthy Aging ,Cellular and Molecular Neuroscience ,Physiology ,business.industry ,Sensory Thresholds ,Physiology (medical) ,Medicine ,Neurology (clinical) ,business - Published
- 2019
26. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy
- Author
-
Jenny L. Davies, Bruce V. Taylor, Michelle M Mauermann, P. James B. Dyck, William J. Litchy, Peter J. Dyck, and Christopher J. Klein
- Subjects
biology ,Physiology ,business.industry ,medicine.medical_treatment ,Mismatch negativity ,Chronic inflammatory demyelinating polyneuropathy ,Immunotherapy ,medicine.disease ,Cellular and Molecular Neuroscience ,Myelin ,Immune system ,medicine.anatomical_structure ,Physiology (medical) ,Immunology ,Office management ,biology.protein ,Medicine ,Neurology (clinical) ,Antibody ,business ,Multifocal motor neuropathy - Abstract
Intravenous immunoglobulin [IVIg], plasma exchange [PE], and corticosteroids are efficacious treatment in chronic inflammatory demyelinating polyneuropathy [CIDP]. IVIg is effective in multifocal motor neuropathy [MMN]. NIS, NIS-weakness, sum scores of raw amplitudes of motor fiber (CMAPs) amplitudes, and Dyck/Rankin score provided reliable measures to detect and scale abnormality and reflect change; they are therefore ideal for office management of response-based immunotherapy (R-IRx) of CIDP. Using efficacious R-IRx, a large early and late therapeutic response (≥ one-fourth were in remission or had recovered) was demonstrated in CIDP. In MMN only an early improvement with late non-significant worsening was observed. The difference in immunotherapy response supports a fundamental difference between CIDP (immune attack on Schwann cells and myelin) and MMN (attack on nodes of Ranvier and axons).
- Published
- 2015
27. Rapid progression of familial amyloidotic polyneuropathy
- Author
-
Zoia Mincheva, William J. Litchy, Jared Gollob, Brian Bettencourt, Pritesh Gandhi, Peter J. Dyck, David H. Adams, Narupat Suanprasert, Laura Obici, Giampaolo Merlini, and Teresa Coelho
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cross-sectional study ,Population ,Severity of Illness Index ,Article ,Internal medicine ,Severity of illness ,Humans ,Medicine ,Age of Onset ,education ,health care economics and organizations ,Aged ,Amyloid Neuropathies, Familial ,education.field_of_study ,Portugal ,biology ,business.industry ,Middle Aged ,medicine.disease ,United States ,Amyloid Neuropathy ,Transthyretin ,Cross-Sectional Studies ,Italy ,Disease Progression ,biology.protein ,Female ,France ,Neurology (clinical) ,Age of onset ,business ,Polyneuropathy ,Natural history study - Abstract
To assess the association between severity of neuropathy and disease stage, and estimate the rate of neuropathy progression in a retrospective cross-sectional analysis of a multinational population of patients with familial amyloidotic polyneuropathy (FAP).We characterize neuropathy severity and rate of progression in available patients with FAP in France, the United States, Portugal, and Italy. Neuropathy Impairment Scores (NIS), time from symptom onset to NIS measurement, polyneuropathy disability (PND) scores, FAP disease stage, and manual grip strength data were collected. We estimated neuropathy progression using Loess Fit and Gompertz Fit models.For the 283 patients studied (mean age, 56.4 years), intercountry genotypic variation in the transthyretin (TTR) mutation was observed, with the majority of patients in Portugal (92%) having early-onset Val30Met-FAP. There was also marked intercountry variation in PND score, FAP stage, and TTR stabilizer use. NIS was associated with PND score (NIS 10 and 99 for scores I and IV, respectively; p0.0001) and FAP stage (NIS 14 and 99 for stages 1 and 3, respectively; p0.0001). In addition, there was an association between NIS and TTR genotype. The estimated rate of NIS progression for a population with a median NIS of 32 was 14.3 points/year; the corresponding estimated rate for the modified NIS+7 is 17.8 points/year.In a multinational population of patients with FAP, rapid neuropathic progression is observed and the severity of neuropathy is associated with functional scales of locomotion.
- Published
- 2015
28. Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria
- Author
-
Sarah E. Berini, Peter J. Dyck, Elizabeth C. Lorenz, Janean K. Engelstad, Jennifer A. Tracy, and Dawn S. Milliner
- Subjects
medicine.medical_specialty ,Pathology ,Kidney ,Physiology ,business.industry ,medicine.medical_treatment ,Calcium oxalate ,medicine.disease ,Oxalate ,Primary hyperoxaluria ,Transplantation ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Physiology (medical) ,Internal medicine ,Renal fibrosis ,Medicine ,Kidney stones ,Neurology (clinical) ,business ,Dialysis - Abstract
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disease caused by a mutation in the alanine-glyoxalate aminotransferase (AGXT) gene which encodes the hepatic enzyme alanine-glyoxylate aminotransferase (AGT). AGT is responsible for converting glyoxylate into glycine. When the enzyme is deficient or defective, glyoxylate accumulates and is converted to oxalate. Oxalate cannot be metabolized and is excreted by the kidneys 4. In PH1, high urinary levels of oxalate lead to kidney stones and deposition of calcium oxalate crystals within the renal tubules and parenchyma, which results in progressive renal fibrosis. As kidney function declines, oxalate production increasingly exceeds renal oxalate clearance. Plasma oxalate levels rise, and insoluble calcium oxalate crystals are deposited in tissues throughout the body, including the kidney, heart, bone, blood vessels, retina, muscle, skin, and nerve. Hemodialysis is needed to remove oxalate from the body, but removal is incomplete, and even when it is intensive, dialysis is often insufficient to prevent progressive systemic oxalate deposition 5,6,7. Because oxalate removal with dialysis is incomplete, the treatment of choice for patients with PH1 and poor kidney function, is combined liver/ kidney transplantation. Liver transplantation is required in the majority of PH type 1 patients to restore the hepatic enzyme defect and protect the renal allograft from recurrent oxalate nephropathy. Significant neurologic improvement in patients with neuropathy has been noted following combined liver and kidney transplantation 8. Only a few case reports have described the nerve pathology associated with primary hyperoxaluria type 1. Demyelination (particularly at the internodes) and axonal degeneration have been reported,1 and some case reports describe crystals in nerve 1,3. The characterization and location of these crystals within nerve has not been well described, and their pathological significance has remained unclear 1,3. In each of these case reports, the patient had significant systemic oxalosis with deposition of oxalate into multiple tissues, whereas the patient we describe had oxalosis affecting peripheral nerve preferentially without other clinically discernible extrarenal manifestations. Approval by our Institutional Review Board and Biospecimens Committee was received for this study.
- Published
- 2015
29. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
- Author
-
David Adams, Jihong Chen, Ole B. Suhr, Raina G. Leahy, Teresa Coelho, Peter J. Dyck, William J. Litchy, and Jared Gollob
- Subjects
Adult ,0301 basic medicine ,medicine.medical_specialty ,Adolescent ,Neural Conduction ,Placebo-controlled study ,Phases of clinical research ,Placebo ,lcsh:RC346-429 ,Body Mass Index ,Study Protocol ,Polyneuropathies ,Young Adult ,03 medical and health sciences ,RNA interference ,0302 clinical medicine ,Diabetic Neuropathies ,Double-Blind Method ,Quality of life ,Polyneuropathy ,Surveys and Questionnaires ,Internal medicine ,APOLLO ,Methods ,medicine ,Humans ,RNA, Small Interfering ,lcsh:Neurology. Diseases of the nervous system ,Aged ,Aged, 80 and over ,business.industry ,mNIS+7 ,Amyloidosis ,General Medicine ,Middle Aged ,medicine.disease ,hATTR amyloidosis ,030104 developmental biology ,Patisiran ,Quality of Life ,Physical therapy ,Neurology (clinical) ,business ,Body mass index ,030217 neurology & neurosurgery ,Progressive disease - Abstract
Background Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Methods Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy. Eligible patients are 18–85 years old with hATTR amyloidosis, investigator-estimated survival of ≥2 years, Neuropathy Impairment Score (NIS) of 5–130, and polyneuropathy disability score ≤IIIb. Patients are randomized 2:1 to receive either intravenous patisiran 0.3 mg/kg or placebo once every 3 weeks. The primary objective is to determine the efficacy of patisiran at 18 months based on the difference in the change in modified NIS+7 (a composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed throughout the study. Discussion APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease. Trial registration This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.
- Published
- 2017
30. Clinical, physiological and pathological characterisation of the sensory predominant peripheral neuropathy in copper deficiency
- Author
-
Sean W. Taylor, Ruple S. Laughlin, Neeraj Kumar, Brent P. Goodman, Christopher J. Klein, P. James B. Dyck, and Peter J. Dyck
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Neural Conduction ,Spinal Cord Diseases ,03 medical and health sciences ,Myelopathy ,0302 clinical medicine ,Sensory ataxia ,medicine ,Autonomic reflex ,Humans ,030212 general & internal medicine ,Pathological ,Neurologic Examination ,business.industry ,Cutaneous nerve ,Peripheral Nervous System Diseases ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,Peripheral neuropathy ,Somatosensory evoked potential ,Surgery ,Female ,Neurology (clinical) ,medicine.symptom ,Copper deficiency ,business ,030217 neurology & neurosurgery ,Copper - Abstract
Myelopathy is considered the most common neurological complication of copper deficiency. Concurrent peripheral neuropathy has been recognised in association with copper deficiency but has not been well characterised.To characterise the clinical, physiological and pathological features of copper-deficient peripheral neuropathy.Patients with simultaneous copper deficiency (0.78 μg/mL) and peripheral neuropathy seen at the Mayo Clinic from 1985 to 2005 were identified.34 patients were identified (median age 55 years, range 36-78) including 24 women and 10 men. Myelopathy was found in 21 patients. Median serum copper level was 0.11 μg/mL (range 0-0.58). The most frequent clinical and electrophysiological pattern of neuropathy was a sensory predominant length-dependent peripheral neuropathy (71%). Somatosensory evoked potentials demonstrated central slowing supporting myelopathy (96%). Quantitative sensory testing demonstrated both small and large fibre involvement (100%). Autonomic reflex screens (77%) and thermoregulatory sweat test (67%) confirmed sudomotor dysfunction. 14 cutaneous nerve biopsies revealed loss of myelinated nerve fibres (86%), increased regenerative clusters (50%), increased rates of axonal degeneration (91%) and increased numbers of empty nerve strands (73%). 71% of biopsies demonstrated epineurial perivascular inflammation.An axonal, length-dependent sensory predominant peripheral neuropathy causing sensory ataxia is characteristic of copper deficiency usually co-occurring with myelopathy. Neurophysiological testing confirms involvement of large, greater than small fibres. The pathological findings suggest axonal degeneration and repair. Inflammatory infiltrates are common but are small and of doubtful pathological significance.
- Published
- 2017
31. Proficiency of nerve conduction using standard methods and reference values (cl. NPhys Trial 4)
- Author
-
Melanie Zwirlein, James W. Russell, Charles F. Bolton, Andrew J. Zafft, Christopher J. Klein, James W. Albers, Rickey E. Carter, James Wolfe, Jenny L. Davies, Nancy Walsh, Peter J. Dyck, Carol J. Overland, and William J. Litchy
- Subjects
medicine.medical_specialty ,Percentile ,Physiology ,business.industry ,Standard methods ,Audiology ,Therapeutic trial ,Cellular and Molecular Neuroscience ,Muscle nerve ,Physiology (medical) ,Multicenter trial ,Reference values ,Physical therapy ,Medicine ,Neurology (clinical) ,Abnormality ,business ,Nerve conduction - Abstract
Introduction The Cl. NPhys Trial 3 showed that attributes of nerve conduction (NC) were without significant intraobserver differences, although there were significant interobserver differences. Methods: Trial 4 tested whether use of written instructions and pretrial agreement on techniques and use of standard reference values, diagnostic percentile values, or broader categorization of abnormality could reduce significant interobserver disagreement and improve agreement among clinical neurophysiologists. Results: The Trial 4 modifications markedly decreased, but did not eliminate, significant interobserver differences of measured attributes of NC. Use of standard reference values and defined percentile values of abnormality decreased interobserver disagreement and improved agreement of judgment of abnormality among evaluators. Therefore, the same clinical neurophysiologist should perform repeat NCs of therapeutic trial patients. Conclusions: Differences in interobserver judgment of abnormality decrease with use of common standard reference values and a defined percentile level of abnormality, providing a rationale for their use in therapeutic trials and medical practice. Muscle Nerve 50: 900–908, 2014
- Published
- 2014
32. Multicenter trial of the proficiency of smart quantitative sensation tests
- Author
-
James W. Albers, William J. Litchy, James W. Russell, Barbara Argyros, P. James B. Dyck, Linde E. Gahnstrom, Susan Nalepa, L. Joseph Melton, Peter J. Dyck, Karen A. Lodermeier, Rickey E. Carter, Christopher J. Klein, Andrew J. Zafft, and Jenny L. Davies
- Subjects
Body surface area ,medicine.medical_specialty ,Reproducibility ,Physiology ,business.industry ,Sensation loss ,Cellular and Molecular Neuroscience ,Physiology (medical) ,Multicenter trial ,Sensory threshold ,Threshold of pain ,Sensation ,Physical therapy ,medicine ,In patient ,Neurology (clinical) ,business - Abstract
Introduction: We assessed proficiency (accuracy and intra- and intertest reproducibility) of smart quantitative sensation tests (smart QSTs) in subjects without and with diabetic sensorimotor polyneuropathy (DSPN). Methods: Technologists from 3 medical centers using different but identical QSTs independently assessed 6 modalities of sensation of the foot (or leg) twice in patients without (n = 6) and with (n = 6) DSPN using smart computer assisted QSTs. Results: Low rates of test abnormalities were observed in health and high rates in DSPN. Very high intraclass correlations were obtained between continuous measures of QSTs and neuropathy signs, symptoms, or nerve conductions (NCs). No significant intra- or intertest differences were observed. Conclusions: These results provide proof of concept that smart QSTs provide accurate assessment of sensation loss without intra- or intertest differences useful for multicenter trials. Smart technology makes possible efficient testing of body surface area sensation loss in symmetric length-dependent sensorimotor polyneuropathies. Muscle Nerve 49: 645–653, 2014
- Published
- 2014
33. O.9Dominant Collagen XII-related myopathy with a distal myopathy phenotype, amenable to treatment with allele-specific knockdown
- Author
-
Daniel Ezzo, A. Foley, Sandra Donkervoort, Ying Hu, Nathan P. Staff, Peter J. Dyck, Dimah Saade, Yaqun Zou, Payam Mohassel, Carsten G. Bönnemann, S. Neuhaus, Richard S. Finkel, Véronique Bolduc, Manuel Koch, Thomas L. Winder, J. Chen, Teerin Liewluck, Klaas J. Wierenga, Charlotte J. Sumner, and L. Medne
- Subjects
Gene knockdown ,Collagen xii ,Neurology ,Pediatrics, Perinatology and Child Health ,medicine ,Neurology (clinical) ,Biology ,medicine.symptom ,Myopathy ,Phenotype ,Molecular biology ,Genetics (clinical) ,Allele specific - Published
- 2019
34. Corrigendum to 'Porphyria: A rare differential diagnosis of polyradiculoneuropathy'. Journal of the Neurological Sciences. Volume 402, 15 July 2019, Pages 153–155
- Author
-
Peter J. Dyck, Neeraj Kumar, Sarah E. Berini, Farwa Ali, and James P. Klaas
- Subjects
medicine.medical_specialty ,Porphyria ,Neurology ,business.industry ,medicine ,Polyradiculoneuropathy ,Neurology (clinical) ,Differential diagnosis ,medicine.disease ,business ,Dermatology ,Volume (compression) - Published
- 2019
35. P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement
- Author
-
Marianne T. Sweetser, S Solomon, PJ Gandhi, D Adams, A Gonzalez-Duarte, Kon-Ping Lin, T Coelho, Peter J. Dyck, Ole B. Suhr, Arnt V. Kristen, John L. Berk, William O'Riordan, J Vest, and Chih-Chao Yang
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,biology ,business.industry ,Amyloidosis ,Cardiomyopathy ,Phases of clinical research ,General Medicine ,medicine.disease ,Placebo ,Transthyretin ,Neurology ,Internal medicine ,medicine ,biology.protein ,Cardiology ,End-diastolic volume ,Medical history ,Neurology (clinical) ,business ,Electrocardiography - Abstract
Background: Hereditary transthyretin-mediated (hATTR) amyloidosis a hereditary, multi-systemic and life-threatening disease resulting in neuropathy and cardiomyopathy. In the APOLLO study, patisiran, an investigational RNAi therapeutic targeting hepatic TTR production resulted in significant improvement in neuropathy and QoL compared to placebo and was generally well tolerated. Methods: APOLLO, a Phase 3 study of patisiran vs. placebo (NCT01960348) prespecified a cardiac subpopulation (n=126 of 225 total) that included patients with baseline left ventricular (LV) wall thickness ≥ 13mm and no medical history of aortic valve disease or hypertension. Cardiac measures included structure and function by electrocardiography, changes in NT-proBNP and 10-MWT gait speed. Results: At 18 months, patisiran treatment resulted in a mean reduction in LV wall thickness of 1 mm (p=0.017) compared to baseline, which was associated with significant improvements relative to placebo in LV end diastolic volume (+8.31 mL, p=0.036), global longitudinal strain (-1.37%, p=0.015) and NT-proBNP (55% reduction, p=7.7 x 10-8) (Figure 1). Gait speed was also improved relative to placebo (+0.35 m/sec, p=7.4 x 10-9). Rate of death or hospitalization was lower with patisiran. mNIS+7 results in the cardiac subpopulation will also be presented. Conclusions: These data suggest patisiran has the potential to halt or reverse cardiac manifestations of hATTR amyloidosis.
- Published
- 2019
36. Does prediabetes cause small fiber sensory polyneuropathy? Does it matter?
- Author
-
Peter J. Dyck, Charles D. Kassardjian, Rickey E. Carter, and Jenny L. Davies
- Subjects
Male ,Pain Threshold ,medicine.medical_specialty ,Article ,Cohort Studies ,Prediabetic State ,Erythromelalgia ,Weight loss ,Internal medicine ,Diabetes mellitus ,Sensation ,Threshold of pain ,medicine ,Humans ,Prediabetes ,Pain Measurement ,Hypoalgesia ,business.industry ,Glucose Tolerance Test ,medicine.disease ,Surgery ,Neurology ,Female ,Neurology (clinical) ,medicine.symptom ,business ,Polyneuropathy - Abstract
Background and objectives The association between prediabetes and distal polyneuropathy (DPN) remains controversial. Here we test whether the prevalence of small fiber sensory distal polyneuropathy is increased in prediabetes. Methods Prospectively recruited cohorts of healthy subjects and those with prediabetes from Olmsted County, Minnesota, were assessed for positive neuropathic sensory symptoms, or pain symptoms characteristic of small fiber sensory DPN. Hyperalgesia and hypoalgesia were assessed by “smart” quantitative sensation testing (QST). The prevalence of symptoms and QST abnormalities were compared among the groups. Results There was no significant increase in the prevalence of positive neuropathic sensory or pain symptoms, nor of hyper- or hypoalgesia in the prediabetes group. There was an increased prevalence of hypoalgesia of the foot only in newly diagnosed diabetes. Conclusions Based on positive sensory and pain symptoms and QSTs, we did not find an increase in small fiber sensory DPN in prediabetes. Recognizing that obesity and diabetes mellitus are implicated in macro- and microvessel complications, physicians should encourage healthy living and weight loss in patients with prediabetes. In medical practice, alternate causes should be excluded before concluding that small fiber sensory distal neuropathy is secondary to prediabetes.
- Published
- 2015
37. A trial of proficiency of nerve conduction: Greater standardization still needed
- Author
-
James W. Albers, L. Joseph Melton, Karen E. Thomas, Rickey E. Carter, Peter J. Dyck, Jenny L. Davies, Andrew J. Zafft, Charles F. Bolton, James W. Russell, Christopher J. Klein, William J. Litchy, Nancy Walsh, and James Wolfe
- Subjects
medicine.medical_specialty ,Electrodiagnosis ,medicine.diagnostic_test ,Standardization ,Physiology ,business.industry ,Disease ,medicine.disease ,Clinical trial ,Cellular and Molecular Neuroscience ,Physiology (medical) ,Epidemiology ,medicine ,Physical therapy ,Neurology (clinical) ,Abnormality ,Nerve conduction ,business ,Polyneuropathy - Abstract
Assessment of signs, symptoms, functional impairments, and nerve tests are the the main clinical measures used for diagnosing and characterizing peripheral nerve disease. Among tests, nerve conduction (NC) has increasingly been advocated for objective electrodiagnosis and characterization of focal, multifocal, or generalized polyneuropathies.1–4 NC is also being used for conducting epidemiological surveys5–7 and therapeutic trials.8,9 For the latter purposes, NC has gained consensus approval,10–13 because its results are considered sensitive, objective, quantitative, and reproducible indications of nerve dysfunction that correlate with clinical signs and symptoms and with neurophysiological and neuropathological abnormalities.14,15 In knowing that assessment of attributes of NC can provide sensitive and quantitative diagnostic and characterizing information about diabetic sensorimotor polyneuropathy (DSPN) for use in medical practice and therapeutic trials, it would also be helpful to learn how accurately and reproducibly within and among clinical neurophysiologists this assessment is done (proficiency). There is already considerable information about test–retest reproducibility of individual attributes of NC focusing mainly on which attributes show the greatest reproducibility and, with this criterion, are suitable for therapeutic trials (albeit test–retest reproducibility is only 1 criterion for such selection). Reproducibility studies have not addressed the issue of proficiency—that is, the variability of NC results among different clinical neurophysiologists without retraining, consensus development, or quality control of their evaluations. Two previous studies have assessed intra- and interobserver variability of measured attributes of NC. In the first study, electromyographers from 1 medical center studied healthy subjects,16 and in a second they studied patients with diabetes mellitus (DM).17 They found no significant intraobserver differences, but significant interobserver differences. They concluded that, for therapeutic trials, it may be advisable to have the same electromyographers perform the sequential NCs over time on patients in the trial. The present trial, Clinical vs. Neurophysiology Trial 3 (Cl vs. NPhys Trial 3) had each group of clinical neurophysiologists and their associate technologist perform NC assessment of 8 attributes of NC of the leg of 24 masked patients with DM without and with DSPN on consecutive days. The expert clinical neurophysiologists were asked to make independent measurements of the attributes without any clinical information, record whether their values were normal or abnormal, and finally make a judgment of whether the abnormalities were diagnostic of DSPN. Thus, these studies specifically addressed 3 questions: (1) Did expert neurophysiologists obtain the same measured values of the 8 attributes of NC without intra- or interobserver differences? (2) Assuming that they did, did they judge abnormality of attributes without intraor interobserver differences? (3) Did they judge DSPN as present or not without intra- or interobserver differences? It was recognized prior to the study that if the first question could not be answered affirmatively, it may not be possible to adequately assess questions (2) and (3). This trial also addresses the broader question of whether further standardization of NC assessment is needed and possible, or whether it is really necessary to have the same electromyographer perform serial evaluations of individual patients. This trial is part of a series of studies organized by Cl vs. NPhys Trial investigators to assess the proficiency of assessment of signs, symptoms, and clinical diagnosis,18,19 attributes of NC (the present Trial 3) and other nerve tests for the diagnosis and characterization of polyneuropathies, especially DSPN. The overall goal is to improve the quality of these evaluations of measures of polyneuropathy in medical practice, medical education, and the conduct of therapeutic trials.
- Published
- 2013
38. DNMT1 mutation hot spot causes varied phenotypes of HSAN1 with dementia and hearing loss
- Author
-
Sarah Lincoln, Thomas D. Bird, Yanhong Wu, Christopher J. Klein, Peter J. Dyck, Nilufer Ertekin-Taner, Georges Mer, Garth A. Nicholson, John B.J. Kwok, and Robert Hjorth
- Subjects
Adult ,Male ,Proband ,Hearing loss ,Biology ,Article ,Diagnosis, Differential ,Exon ,Alzheimer Disease ,medicine ,Humans ,Dementia ,Hereditary Sensory and Autonomic Neuropathies ,Hearing Loss ,Aged ,Narcolepsy ,Genetics ,Cerebellar ataxia ,Middle Aged ,medicine.disease ,Pedigree ,Repressor Proteins ,Phenotype ,Frontotemporal Dementia ,Mutation ,Female ,Neurology (clinical) ,Alzheimer's disease ,medicine.symptom ,Frontotemporal dementia - Abstract
Background: Mutations in DNA methyltransferase 1 (DNMT1) have been identified in 2 autosomal dominant syndromes: 1) hereditary sensory autonomic neuropathy with dementia and hearing loss (HSAN1E); and 2) cerebellar ataxia, deafness, and narcolepsy. Both syndromes have mutations in targeting sequence (TS) domain (exons 20–21), which is important in mediating DNA substrate binding to the DNMT1 catalytic domain. Frontal lobe hypometabolism has been documented in an HSAN1E family, but memory loss has been the primary cognitive complaint. The chromosomal location of the DNMT1 gene at 19p13.2 has been linked to familial late-onset Alzheimer disease. Methods: We sequenced 41 exons of DNMT1 and their flanking regions in 1) 2 kindreds with HSAN1E; 2) 48 patients with HSAN1 alone without dementia and hearing loss; and 3) 5 probands of familial frontotemporal dementia (FTD) kindreds. We also sequenced exon 20 and 21 in 364 autopsy-confirmed late-onset Alzheimer disease cases. Results: Mutations in DNMT1 were specific to 2 HSAN1E kindreds with dementia and hearing loss (no narcolepsy). One family carried previously identified mutation Tyr495Cys; the other carried a novel Tyr495His, both in the TS domain. The symptoms of these patients include prominent personality, psychiatric manifestations, and seizures in one and the onset time is later than the previously reported cases. Conclusion: Clinicians should consider DNMT1 mutations in patients presenting with FTD or primary memory decline who also have sensory neuropathy and hearing loss. Amino acid Tyr495 is a hot spot for HSAN1E, distinct from exon 21 mutations associated with narcolepsy.
- Published
- 2013
39. Surgical and postpartum hereditary brachial plexus attacks and prophylactic immunotherapy
- Author
-
Peter J. Dyck, Toby N. Weingarten, Christopher J. Klein, David W. Barbara, and Juraj Sprung
- Subjects
Brachial Plexus Neuritis ,medicine.medical_specialty ,Physiology ,business.industry ,medicine.medical_treatment ,Neuritis ,Thyroidectomy ,Laminectomy ,Perioperative ,Surgery ,Cellular and Molecular Neuroscience ,Physiology (medical) ,Anesthesia ,Medicine ,Caesarean section ,Neurology (clinical) ,business ,Brachial plexus ,Postpartum period - Abstract
Introduction: Surgery and childbirth can trigger attacks of hereditary brachial plexus neuropathy (HBPN), and inflammation was suggested as a component of the pathogenesis. Methods: HBPN patients who underwent surgery or parturition from January 1, 1996 to December 31, 2009 were studied. Results: Twenty-five HBPN patients underwent 48 surgeries or parturitions. Seventeen patients (68%) had attacks, including 13 periprocedural and 7 postpartum by varied anesthesia types. Three patients who had 8 earlier combined attacks (after thyroidectomy, laminectomy, and Caesarean section) were given prophylactic immunosuppressive therapy (corticosteroids ± immunoglobulin). None suffered postoperative attacks, which is uncharacteristic of their prior experience. Five had perioperative attacks as their first HBPN manifestation. Median follow-up was 11 months (3–48 months). Attacks occurred in the operated limb (n = 6) or distant (n = 7) to surgical sites. All attacks interfered with daily living, with frequent incomplete recovery. Five patients had a SEPT9 mutation. Conclusions: Corticosteroids may prevent parturition and surgical HBPN attacks in some patients. Diverse surgeries, anesthesia, and childbirth frequently trigger HBPN attacks. Muscle Nerve, 2013
- Published
- 2012
40. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy
- Author
-
Juan J. Figueroa, Rami Massie, P.J.B. Dyck, Peter J. Dyck, Ruple S. Laughlin, Phillip A. Low, J.A. Mercado, and Paola Sandroni
- Subjects
Adult ,Male ,medicine.medical_specialty ,Sweating ,Autonomic Nervous System ,Severity of Illness Index ,Heart Rate ,Internal medicine ,Severity of illness ,medicine ,Autonomic reflex ,Humans ,Anhidrosis ,Pure autonomic failure ,business.industry ,Dysautonomia ,Polyradiculoneuropathy ,Articles ,Middle Aged ,medicine.disease ,Sudomotor ,Autonomic nervous system ,Autonomic Nervous System Diseases ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Physical therapy ,Cardiology ,Female ,Neurology (clinical) ,medicine.symptom ,business ,Body Temperature Regulation - Abstract
Objectives: Autonomic deficits in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have not been adequately quantitated. The Composite Autonomic Severity Score (CASS) is a validated instrument for laboratory quantitation of autonomic failure derived from standard autonomic reflex tests. We characterized dysautonomia in CIDP using CASS. Methods: Autonomic function was retrospectively analyzed in 47 patients meeting CIDP criteria. CASS ranges from 0 (normal) to 10 (pandysautonomia), reflecting summation of sudomotor (0–3), cardiovagal (0–3), and adrenergic (0–4) subscores. Severity of neurologic deficits was measured with Neuropathy Impairment Score (NIS). Degree of small fiber involvement was assessed with quantitative sensation testing. Thermoregulatory sweat test (TST) was available in 8 patients. Results: Patients (25 men) were middle-aged (45.0 ± 14.9 years) with longstanding CIDP (3.5 ± 4.3 years) of moderate severity (NIS, 46.5 ± 32.7). Autonomic symptoms were uncommon, mainly gastrointestinal (9/47; 19%) and genitourinary (8/47; 17%). Autonomic deficits (CASS ≥1) were frequent (22/47; 47%) but very mild (CASS, 0.8 ± 0.9; CASS ≤3, all cases). Deficits were predominantly sudomotor (16/47; 34%) and cardiovagal (10/47; 21%) with relative adrenergic sparing (4/47; 9%). TST was abnormal in 5 of 8 patients (anhidrosis range, 2%–59%). Sudomotor impairment was predominantly distal and postganglionic. Somatic deficits (disease duration, severity, small fiber deficits) did not predict presence of autonomic deficits. Conclusion: Our data characterize the autonomic involvement in classic CIDP as mild, cholinergic, and predominantly sudomotor mainly as a result of lesions at the distal postganglionic axon. Extensive or severe autonomic involvement (CASS ≥4) in suspected CIDP should raise concern for an alternative diagnosis.
- Published
- 2012
41. Vasculitic neuropathy following exposure to minocycline
- Author
-
P. James B. Dyck, Janean K. Engelstad, John M. Baratta, Brent P. Goodman, Pariwat Thaisetthawatkul, Chafic Karam, Patricio Brand, and Peter J. Dyck
- Subjects
medicine.medical_specialty ,Weakness ,Pathology ,medicine.disease_cause ,Article ,Autoimmunity ,Mononeuropathy ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Stroke ,Acne ,030203 arthritis & rheumatology ,Muscle biopsy ,medicine.diagnostic_test ,business.industry ,Minocycline ,medicine.disease ,Dermatology ,3. Good health ,Neurology ,Neurology (clinical) ,medicine.symptom ,business ,Vasculitis ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Objective: To report 3 patients with minocycline-induced autoimmunity resulting in peripheral nerve vasculitis. Methods: We report 3 patients who, during minocycline treatment for acne vulgaris, developed subacute onset of pain and weakness caused by vasculitis in single and multiple mononeuropathy patterns. Results: Each patient underwent either a nerve or muscle biopsy that confirmed vasculitis. One patient additionally developed systemic symptoms (including fever, fatigue, and night sweats) and another had a posterior circulation stroke. Symptoms developed with either early or prolonged use of minocycline. Despite withdrawal of minocycline, patients needed long-term immunotherapy to gain neurologic improvement. Conclusions: Our findings suggest that the typical neuropathy associated with minocycline use is painful single or multiple mononeuropathy due to peripheral nerve vasculitis, which may also be accompanied by presumed CNS vasculitis (presenting as stroke).
- Published
- 2015
42. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy
- Author
-
William J. Litchy, Peter J. Dyck, and Rickey E. Carter
- Subjects
Neural Conduction ,medicine.medical_specialty ,Percentile ,Diabetic neuropathy ,Physiology ,business.industry ,Sural nerve ,medicine.disease ,Surgery ,Cellular and Molecular Neuroscience ,medicine.anatomical_structure ,Physiology (medical) ,Internal medicine ,Diabetes mellitus ,medicine ,Cardiology ,Neurology (clinical) ,Ulnar nerve ,Tibial nerve ,business ,Sensory nerve - Abstract
Introduction: In this study we aimed to deter- mine which criteria are valid for nerve conduction (NC) diagno- sis of typical diabetic sensorimotor polyneuropathy (DSPN). Methods: Eight criteria were assessed from among diabetes databases, the Rochester Diabetic Neuropathy Study (RDNS, N ¼ 456), and in healthy subjects (RDNS-HS, N ¼ 330). Results: In the RDNS, the most frequent abnormal attributes (� 2.5th/� 97.5th percentile) are: fibular motor nerve conduction velocity (MNCV; 26.3%); sural sensory nerve conduction veloc- ity (SNAP; 25.4%); tibial MNCV (24.8%); ulnar MNCV (21.3%); fibular F latency (16.9%); and ulnar F latency (16.0%). Normal deviate (from percentiles) composite scores of NC included: representative of neurophysiological abnormalities; sensitive and specific for diagnosis and useful for epidemiological sur- veys; randomized trials; and medical practice. By contrast, abnormality of one or more attributes in any nerve or abnormally of two most sensitive attributes performed poorly. Conclusions: Composite sum scores of normal deviates (from percentiles corrected for applicable variables) of sensitive NC attributes and with modifications, RDNS and AAN criteria per- formed acceptably for diagnosis of DSPN. Muscle Nerve 44: 340-345, 2011
- Published
- 2011
43. Vasculitic Neuropathy Associated With Minocycline Use
- Author
-
Peter J. Dyck, Pariwat Thaisetthawatkul, Robert Sundell, and Carrie E. Robertson
- Subjects
Adult ,Vasculitis ,medicine.medical_specialty ,Minocycline ,Autoimmune hepatitis ,Mononeuropathy ,Necrotizing Vasculitis ,medicine ,Humans ,Systemic lupus erythematosus ,business.industry ,Mononeuropathies ,General Medicine ,medicine.disease ,Dermatology ,Anti-Bacterial Agents ,Surgery ,Treatment Outcome ,Peripheral neuropathy ,Neurology ,Methylprednisolone ,Female ,Neurology (clinical) ,Sciatic Neuropathy ,business ,medicine.drug - Abstract
Introduction Minocycline is an antibiotic used for the treatment of acne. It has been associated with several autoimmune syndromes, including drug-induced lupus, autoimmune hepatitis, and vasculitis. Method and results We report a case of a 28-year-old previously healthy woman who developed a left sciatic mononeuropathy 2 weeks after starting minocycline for acne. Magnetic resonance imaging studies supported the localization. A biopsy of the left sural nerve revealed acute nerve large arteriole necrotizing vasculitis. Her condition improved after the withdrawal of minocycline and a course of treatment with methylprednisolone. Conclusion This case provides further evidence that minocycline may induce a nonsystemic necrotizing vasculitis.
- Published
- 2011
44. The Neuropathies of Waldenström's Macroglobulinemia (WM) and IgM-MGUS
- Author
-
Steven R. Zeldenrust, Christopher J. Klein, Angela Dispenzieri, Yanhong Wu, Joon Shik Moon, Michelle L. Mauermann, and Peter J. Dyck
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Neural Conduction ,Paraproteinemias ,Article ,Statistics, Nonparametric ,Nerve conduction velocity ,Hemoglobins ,Polyneuropathies ,Sural Nerve ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Nerve biopsy ,medicine.diagnostic_test ,business.industry ,Waldenstrom macroglobulinemia ,Macroglobulinemia ,General Medicine ,Middle Aged ,medicine.disease ,Axons ,Amyloid Neuropathy ,Peripheral neuropathy ,Immunoglobulin M ,Neurology ,Female ,Neurology (clinical) ,Waldenstrom Macroglobulinemia ,business ,Polyneuropathy ,Monoclonal gammopathy of undetermined significance - Abstract
In the evaluation of a patient with peripheral neuropathy the discovery of a serum monoclonal protein has implications for the neurologic and hematologic diagnosis, prognosis and treatment1. Among such patients the type of neuropathy may suggest the specific underlying hematologic process. To illustrate, in a patient with a monoclonal protein having subacute painful multiple mononeuropathies the diagnosis of mixed cryoglobulinemia is likely and evaluation for viral hepatitis should be emphasized. In another patient, also with a monoclonal protein and with insidious onset of a symmetric painful autonomic, sensory motor polyneuropathy, primary amyloid light chain (AL) amyloidosis should be suspected. In a third example a monoclonal protein with insidious demyelinating polyradiculoneuropathy occurs in POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M spike and Skin changes) and should lead to search of treatable osteosclerotic myeloma2. Familiarity of these patterns, and others, leads to correct diagnosis and treatment. Among persons having IgM-MGUS an insidious painless distal sensory ataxic neuropathy with demyelination has been felt to be so characteristic as to coin the acronym DADS (Distal, Acquired, Demyelinating, Sensory-neuropathy)3. By contrast descriptions of the neuropathy features occurring in another IgM condition, namely Waldenstrom’s macroglobulinemia (WM) are limited4,5. Waldenstrom’s macroglobulinemia is defined by the Revised European American Lymphoma (REAL) and World Health Organization (WHO) as having a bone marrow (BM) infiltrated lymphoplasmacytic lymphoma and IgM paraproteinemia6. In WM the hematologic features of anemia, hepatosplenomegaly, lymphadenopathy, and hyperviscosity have previously been reported but are variably present with current requirement of BM diagnosis7. Some investigators have suggested there are more axonal features in the nerve conduction studies (NCS) in WM, but the diagnosis of WM did not appear to be based on current BM criteria4,5. By contrast, distal, symmetric, chronic demyelinating neuropathy is more commonly described in IgM-MGUS neuropathy patients3,8 including the reports of reduced terminal latency index (TLI), indicating relative slowing in distal motor nerve segments9–11. Tremor has also been described to be one of the possible clinical stigmata of the IgM-MGUS neuropathy12. Some studies have suggested that the existence of myelin-associated glycoprotein antibodies (anti-MAG) may explain the clinical, electrophysiologic, and histologic features of the DADS-IgM-MGUS neuropathy13–15. However, other studies of IgM neuropathy have found little or no difference between the type and severity of neuropathies in IgM patients with or without anti-MAG antibodies16,17. The MAG antibodies are commonly present in IgM amyloid neuropathy and IgM patients without neuropathy and therefore are not routinely used for diagnosis at many institutions including our own18. We conducted this retrospective review to characterize the neuropathies associated with WM and IgM-MGUS to answer whether there are clinical, electrophysiologic and nerve biopsy findings that distinguish the neuropathies associated with WM from IgM-MGUS. In an attempt to study distal predominant involvements we use the previously published formulas to calculate the residual latency (RL) and TLI from routine NCS. The RL19 is a subtraction of the calculated latency from the measured latency. It evaluates the distal segment of the motor nerves and has been reported to be associated with the neuropathy associated with IgM-MGUS20. The TLI is the ratio between the calculated latency [distance/motor conduction velocity (MCV)] and the measured latency, i.e. distal motor latency (DML) and also assesses for selective distal conduction velocity slowing9–11,21.
- Published
- 2011
45. Motor neuron disease due to neuropathy target esterase gene mutation: Clinical features of the index families
- Author
-
Peter J. Dyck, Shirley Rainier, John K. Fink, Rudy J. Richardson, O. Petter Eldevik, James W. Albers, and Sandra Wilcock
- Subjects
biology ,Physiology ,business.industry ,Neuropathy target esterase ,Motor neuron ,Gene mutation ,medicine.disease ,Lower motor neuron ,Cellular and Molecular Neuroscience ,Degenerative disease ,medicine.anatomical_structure ,Atrophy ,Physiology (medical) ,medicine ,biology.protein ,Neurology (clinical) ,Spasticity ,medicine.symptom ,Amyotrophic lateral sclerosis ,business ,Neuroscience - Abstract
Recently, we reported that mutations in the neu- ropathy target esterase (NTE) gene cause autosomal recessive motor neuron disease (NTE-MND). We describe clinical, neuro- physiologic, and neuroimaging features of affected subjects in the index families. NTE-MND subjects exhibited progressive lower extremity spastic weakness that began in childhood and was later associated with atrophy of distal leg and intrinsic hand muscles. NTE-MND resembles Troyer syndrome, except that short stature, cognitive impairment, and dysmorphic fea- tures, which often accompany Troyer syndrome, are not fea- tures of NTE-MND. Early onset, symmetry, and slow progression distinguish NTE-MND from typical amyotrophic lat- eral sclerosis. NTE is implicated in organophosphorus com- pound-induced delayed neurotoxicity (OPIDN). NTE-MND patients have upper and lower motor neuron deficits that are similar to OPIDN. Motor neuron degeneration in subjects with NTE mutations supports the role of NTE and its biochemical cascade in the molecular pathogenesis of OPIDN and possibly other degenerative neurologic disorders. Muscle Nerve 43: 19-25, 2011
- Published
- 2010
46. Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies
- Author
-
Martin Lammens, Claudia Sommer, Ersin Tan, Andoni Urtizberea, Carmen Navarro, Joachim Weis, Yadollah Harati, Sebastian Brandner, Henry C. Powell, Angelo Schenone, Laurent Magy, Svein Ivar Mellgren, Peter J. Dyck, Michela Morbin, and Catherine LaCroix
- Subjects
medicine.medical_specialty ,Nerve biopsy ,medicine.diagnostic_test ,business.industry ,Biopsy ,General Neuroscience ,MEDLINE ,Peripheral Nervous System Diseases ,Diagnostic test ,Guideline ,Surgery ,Informed consent ,Peripheral nerve ,Clinical information ,Perception and Action [DCN 1] ,medicine ,Humans ,Medical physics ,Neurology (clinical) ,business - Abstract
Item does not contain fulltext Nerve biopsy is often the final step in the diagnostic work-up of neuropathies of unknown origin. The aim of this guideline was to prepare an evidence-based guideline on the methods for performing and evaluating nerve biopsy. The panel performed a search of MEDLINE, hand search of bibliographies of the references retrieved, review of the evidence, and reached agreement by consensus. There were not enough formal studies of diagnostic test accuracy to allow evidence-based recommendations of levels A-C for most questions. The panel summarized the class IV evidence and reached agreement by consensus on the following recommendations: (1) Nerve biopsy should not be performed before adequate clinical, electrophysiological, and laboratory investigation and only be performed with appropriate informed consent. (2) An interactive working relationship with the relevant disciplines involved and the provision of sufficient clinical information is encouraged. (3) Biopsies should be processed and read by professionals with adequate training and experience. (4) Optimal analysis of nerve biopsy is best performed by laboratories that have the facilities and expertise to prepare and evaluate frozen and fixed sections (cryostat, paraffin, and epoxy sections). (5) Immunohistochemistry, teased fiber analysis, electron microscopy, and morphometry may help clarify the diagnosis in some conditions and should be considered as additional studies. 01 september 2010
- Published
- 2010
47. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial
- Author
-
P. James B. Dyck, William J. Litchy, J. Gareth Llewelyn, James W. Albers, Carol J. Overland, Wolfgang Singer, Jenny L. Davies, Solomon Tesfaye, James W. Russell, Michelle L. Mauermann, Peter C. O'Brien, Peter J. Dyck, John D. England, Phillip A. Low, Charles F. Bolton, Christopher J. Klein, Henning Andersen, Adrian Vella, and A. Gordon Smith
- Subjects
medicine.medical_specialty ,Physiology ,business.industry ,Signs and symptoms ,Sensorimotor polyneuropathy ,Gold standard (test) ,medicine.disease ,Surgery ,Cellular and Molecular Neuroscience ,Muscle nerve ,Physiology (medical) ,Internal medicine ,Diabetes mellitus ,medicine ,Neurology (clinical) ,Medical diagnosis ,business ,Nerve conduction ,Polyneuropathy - Abstract
The purpose was to test whether physicians can validly and reproducibly diagnose diabetic sensorimotor poly- neuropathy (DSPN). Twelve physicians assessed 24 patients with diabetes mellitus (DM) on consecutive days (576 examina- tions) with physical features and voice disguised. Results were compared to gold standard 75% group diagnosis (dx) and a nerve conduction score (R5 NC nds). Masking of patients was achieved. Reproducibility measured by the kappa coefficient and compared to R5 NC nd varied considerably among physi- cians: median and ranges: signs 0.8 (0.32-1.0); symptoms 0.79 (0.36-1.0), and diagnoses 0.47 (0.33-0.84), both low and high scores indicating poor performance. There was substantial agreement between 75% group dx and confirmed NC abnor- mality (abn). As compared to R5 NC, individual physicians' clini- cal dx was excessively variable and frequently inaccurate. Study physician dx from signs and symptoms were excessively variable, often overestimating DSPN. Specific approaches to improving clinical proficiency should be tested. Muscle Nerve 42: 157-164, 2010
- Published
- 2010
48. Primary amyloidosis presenting as upper limb multiple mononeuropathies
- Author
-
Jennifer A. Tracy, Peter J. Dyck, and P. James B. Dyck
- Subjects
Pathology ,medicine.medical_specialty ,Physiology ,Biopsy ,Neuritis ,Neural Conduction ,Amyloid Neuropathies ,Sensitivity and Specificity ,Article ,Diagnosis, Differential ,Mononeuropathy ,Antibodies, Monoclonal, Murine-Derived ,Cellular and Molecular Neuroscience ,Predictive Value of Tests ,Physiology (medical) ,medicine ,Humans ,Peripheral Nerves ,Treatment Failure ,Aged ,Nerve biopsy ,medicine.diagnostic_test ,Mononeuritis Multiplex ,business.industry ,Electrodiagnosis ,Amyloidosis ,Mononeuropathies ,Antibodies, Monoclonal ,Immunoglobulins, Intravenous ,medicine.disease ,Amyloid Neuropathy ,Peripheral neuropathy ,Arm ,Disease Progression ,Female ,Immunoglobulin Light Chains ,Neurology (clinical) ,Differential diagnosis ,Rituximab ,business ,Biomarkers - Abstract
Peripheral neuropathy in primary (AL) amyloidosis is usually lower limb predominant, length-dependent, symmetrical, and affects small (pain and autonomic) fibers, as much or more than large fibers. We report a patient with step-wise progressive, multiple upper limb mononeuropathies that were due to nerve biopsy-proven primary amyloidosis (lambda light chain), with no systemic or autonomic features. Recognition that light chain amyloidosis may be the cause of a multiple mononeuropathy pattern adds to the differential diagnosis of this clinical phenotype.
- Published
- 2010
49. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy
- Author
-
Steven R. Zeldenrust, Dong Hwee Kim, Peter J. Dyck, and Phillip A. Low
- Subjects
Pathology ,medicine.medical_specialty ,biology ,Physiology ,business.industry ,Amyloidosis ,medicine.disease ,Cellular and Molecular Neuroscience ,Transthyretin ,medicine.anatomical_structure ,Physical medicine and rehabilitation ,Physiology (medical) ,Peripheral nervous system ,Sensation ,Severity of illness ,medicine ,biology.protein ,Autonomic reflex ,Neurology (clinical) ,business ,Polyneuropathy ,Sensory nerve - Abstract
This study assesses the value of standard quantitative autonomic (QAT) and sensation (QST) tests in detecting, characterizing, and quantitating the severity of transthyretin amyloid polyneuropathy (TTR-A-PN). This information is needed for prospective therapeutic trials, epidemiologic surveys, and medical practice. We reviewed 36 patients with TTR-A-PN who were evaluated between 1997 and 2007. They had neurologic, genetic, electrodiagnostic, and autonomic reflex screen evaluations and allowed their medical records and test results to be evaluated for research purposes. Of these, 22 patients had also been tested by quantitative sensation tests (QSTs). The median symptom duration was 4 years (range 1–30 years). Among quantitative nerve tests evaluated, composite scores of nerve conduction (Σ5 NC nds), a composite score of QSTs (Σ3 QST nds), and quantitative autonomic tests (QSART, HRdb, and CASS) gave high frequencies of abnormality. The results show that peripheral autonomic and small-fiber sensory dysfunction was prominent and characteristic of most of the patients we studied. However, this involvement was not selective for small-diameter sensory and autonomic nerve fibers; large motor and sensory fibers were also shown to be dysfunctional. Dysfunction of large fibers was approximately as frequent as that of small fibers. This study provides a rationale for the use of QAT, QST, and Σ5 NC nds as standard, objective, and quantitative measures for assessing the severity of TTR-A-PN in epidemiologic surveys, therapeutic trials, and medical practice. Muscle Nerve, 2009
- Published
- 2009
50. Longitudinal study of intraneural perineurioma--a benign, focal hypertrophic neuropathy of youth
- Author
-
Nancy L. Kuntz, P. James B. Dyck, Peter J. Dyck, JaNean Engelstad, Robert J. Spinner, Joel P. Felmlee, Kimberly K. Amrami, Michelle L. Mauermann, and E. Peter Bosch
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Biopsy ,Nerve Sheath Neoplasms ,Mononeuropathy ,Young Adult ,Perineurioma ,Peripheral Nervous System Neoplasms ,Peripheral Nervous System ,Humans ,Medicine ,Child ,Ulnar nerve ,Movement Disorders ,business.industry ,Median Neuropathy ,Sensory loss ,Original Articles ,Hypertrophy ,Middle Aged ,Prognosis ,medicine.disease ,Magnetic Resonance Imaging ,Intraneural perineurioma ,Surgery ,Peripheral neuropathy ,Child, Preschool ,Sensation Disorders ,Disease Progression ,Female ,Neurology (clinical) ,Epidemiologic Methods ,business ,Nerve sheath neoplasm - Abstract
The natural history of intraneural perineurioma has been inadequately studied. The aim of this study was to characterize the clinical presentation, electrophysiologic and imaging features and outcome of intraneural perineurioma. We ask if intraneural perineurioma is a pure motor syndrome that remains confined to one nerve and should be treated by surgical resection. We examined the nerve biopsies of cases labelled perineurioma and selected those with diagnostic features. Thirty-two patients were identified; 16 children and 16 adults; 16 males and 16 females. Median age of onset of neurological symptoms was 14 years (range 0.5-55 years) and median age at evaluation was 17 years (range 2-56 years). All patients had motor deficits; however, mild sensory symptoms or signs were experienced by 27 patients; 'prickling' or 'asleep numbness' in 20, mild pain in 13 and sensory loss in 23. The sciatic nerve or its branches was most commonly affected in 15, followed by brachial plexus, radial nerve and ulnar nerve (four each). Magnetic resonance imaging demonstrated nerve enlargement (29/32), T1 isointensity (27/32), T2 hyperintensity (25/32) and contrast enhancement (20/20). Diagnoses were made based on targeted biopsy of the focal nerve enlargement identified by imaging. Neurological impairment was of a moderate severity (median Neuropathy Impairment Score was 12 points, range 2-49 points). All patients had focal involvement with 27 involving one nerve and five involving a plexus (one bilateral). Long-term follow-up was possible by telephone interview for 23 patients (median 36 months, range 2-177 months). Twelve patients also had follow-up neurologic evaluation (median 45 months, range 10-247 months). The median Neuropathy Impairment Score had changed from 12.6 to 15.4 points (P = 0.19). In all cases, the distribution of neurologic findings remained unchanged. Median Dyck Disability Score was 3 (range 2-5) indicating a mild impairment without interfering with activities of daily living. Ten patients judged their symptoms unchanged, nine slightly worse and four slightly better. We conclude intraneural perineurioma is a benign hypertrophic (non onion bulb) peripheral nerve tumour that presents insidiously in young people and is motor predominant with mild sensory involvement. It is most often a mononeuropathy, but a plexopathy can occur. Diagnosis of this condition requires clinical suspicion, imaging, targeted fascicular biopsy of the lesion and expertise of nerve pathologists. As these tumours are static or slowly progressive, remain confined to their original distribution and have low morbidity, they probably should not be resected routinely. Because intensive evaluation is needed for diagnosis, intraneural perineurioma is probably under-recognized.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.